

AD _____

Award Number: DAMD17-98-1-8327

TITLE: Ex Vivo Expanded (EVE) Megakaryocytes (MK) for Supportive
Care of Patients with Breast Cancer Hematologic
Malignancies: A Phase I/II Clinical Study

PRINCIPAL INVESTIGATOR: Isaac Cohen, Ph.D.

CONTRACTING ORGANIZATION: Northwestern University
Evanston, Illinois 60208

REPORT DATE: December 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Best Available Copy

20040324 006

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE December 2003	3. REPORT TYPE AND DATES COVERED Final (15 Sep 1998 - 30 Nov 2003)	
4. TITLE AND SUBTITLE Ex Vivo Expanded (EVE) Megakaryocytes (MK) for Supportive Care of Patients with Breast Cancer Hematologic Malignancies: A Phase I/II Clinical Study			5. FUNDING NUMBERS DAMD17-98-1-8327	
6. AUTHOR(S) Isaac Cohen, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Northwestern University Evanston, Illinois 60208 <i>E-Mail:</i> i-c@northwestern.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) The main goal of this project is to culture blood stem cells in the presence of human hematopoietic growth factors to produce autologous megakaryocytes (MK) to be transfused into patients as a supplement to the conventional stem cell autograft. The purpose of the clinical trial is to determine whether the transfused MK will generate platelets in vivo in great enough numbers to reduce or eliminate the need for repeated platelet transfusions following high-dose chemotherapy and autologous stem cell transplant. We determined in pre-clinical experiments that a cocktail of the growth factors thrombopoietin, IL-3 and Flt3-L and high seeding cell density were necessary to optimize the ex vivo expansion of MK. We successfully transplanted three patients. Cell expansion was optimal after six days, no negative reactions were observed, and the patients recovered normal platelet levels fast with normal platelet function. This study shows that using an ex vivo expanded product is feasible, and the successful outcome in our three transplanted patients augurs well for future use of this concept. Additionally, we have added a novel survival factor, PLP-E to the arsenal of growth factors used for ex vivo myeloid expansion and have elucidate the molecular mechanism of proplatelet formation.				
14. SUBJECT TERMS Breast cancer, malignancy, platelets, megakaryocytes, ex vivo expansion			15. NUMBER OF PAGES 62	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5 - 14
Key Research Accomplishments.....	14 - 15
Reportable Outcomes.....	15 - 16
Conclusions.....	16
References.....	17
Appendices.....	18 - 59

INTRODUCTION:

The primary objective of this project is to culture blood stem cells in the presence of human hematopoietic growth factors to produce autologous megakaryocytes (MK) to be transfused into patients as a supplement to the conventional stem cell autograft. The purpose of the clinical trial is to determine whether the transfused MK will generate platelets *in vivo* in great enough numbers to reduce or eliminate the need for repeated platelet transfusions following high-dose chemotherapy and autologous stem cell transplant. Although they decrease the risk of fatal bleeding complications, repeated platelet transfusions increase the risk of bacterial and viral infections, alloimmunization and transfusion reactions.[1] When this study was initiated, no FDA-approved megakaryocyte-specific growth factors were available for clinical use. We therefore had to resort to growth factors being developed by pharmaceutical companies, and seek FDA approval for their use in this study.

As described in our previous reports, the study was plagued throughout with pitfalls originating from the pharmaceutical industry canceling on more than one occasion their prior approval for using their products. Often this happened following several months of painstaking laboratory investigation with results published in scientific publications. As a result, we were not able to adhere to the timeline described in the Statement of Work. Our initial grant proposal was based on growth factors provided by GD Searle & Co. (Promegapoeitin (PMP) and Progenipoeitin (PGP)[2]), which was later acquired by Pharmacia, which terminated the PMP/PGP growth factor development program.

We then repeated our pre-clinical laboratory investigations[3] with the use of Megakaryocyte Growth and Development Factor (MGDF) from Amgen, which, in combination with Stem Cell Factor (SCF), yielded an excellent growth factor cocktail.[4] Unfortunately, Amgen decided to remove MGDF from clinical development.

With considerable effort, we were able to generate similar preclinical data using a growth factor combination obtained from a variety of sources including Immunex (Flt3L) and R&D Systems, Inc. (thrombopoietin -TPO- and IL-3).[5] Our study was revised, an IND submitted and approved by the FDA, and our first patient entered. The results obtained were very encouraging with full platelet recovery occurring at day 6 post-transplant. This unusual rapid recovery must be attributed to the *ex vivo*-expanded cells. Midway into processing the expanded megakaryocytes for our second patient, we were notified that the FDA was no longer permitting the use of the TPO obtained from R&D Systems because of concerns regarding the purification process. This new obstacle caused us to abort the culture for the second patient. This new concern on the part of the FDA has affected cellular therapy research at many other centers.

We then found an alternative source of clinical grade TPO manufactured by Pharmacia using purification procedures approved by the FDA. In the meantime, Amgen acquired Immunex and then Pfizer acquired Pharmacia. These reorganizations caused further delays with respect to licensing issues surrounding our use of Flt-3L and TPO, including considerable time required to draft contracts between Amgen, Pfizer, and our Office of Research and Sponsored Projects. Finally, the accrual of potential candidates has also been hampered by either the restrictions that we had established in our clinical trial protocol, the consent of the patient, and diminished willingness of health insurance providers to allow their customers to go on study, due to their reduced risk tolerance in the wake of falling financial returns.

We have decided to stop the clinical trial in view of the termination of our funding period. All in all, of the six patients who were accrued, three patients were transplanted successfully. While the megakaryocytes expanded optimally for the other three patients, they could not be transplanted for reasons discussed in the Body description. This study showed that using an *ex vivo*-expanded product is feasible and the successful outcome in our three transplanted patients augurs well for future use of this concept.

While our translational project was stalled, we also investigated means to improve expansion of human MK in vitro and determined the signaling mechanism of platelet production.

BODY:

Materials and Methods Used for Pre-Clinical Trial (summary from annual reports 01 to 03).

Low density nonadherent mononuclear cells were prepared from bone marrow and peripheral blood progenitor cells. CD34+ cells were purified using immunomagnetic procedures. For small scale cultures, an average of 90.7% of cells were viable with an average purity of 81%. For large scale cultures an average of 82% cells were viable with an average purity of 97% as assessed by flow cytometry. The cells were cultured at a density of 4×10^5 cells per ml of X-vivo-20 medium supplemented with a cocktail composed of thrombopoietin (TPO) and non-specific fast proliferating cytokines (IL-3 and Flt3-L). The expansion of early and late MK was monitored by flow cytometry and clonogenic assays.

Materials and Methods Used for Clinical Trial (spanning annual report 04 and last one) [6]

Equipment

- 37° water bath, Scientific Products
- Class B sterile tissue culture hood, Baker Co.
- Clinical bench centrifuge, Beckman.
- 37° tissue culture incubator, 5% CO₂, Forma Scientific.
- Variable adjustable electronic pipettor, EDP, Rainin.
- Vacuum-driven automatic pipet device, Drummond.
- Coulter Epics XL 3-color laser flow cytometer, BeckmanCoulter Corp.

Materials

- Sterile pipet tips with aerosol barrier.
- Sterile individually wrapped polypropylene transfer pipets.
- 2ml, 5ml, 10ml, 25ml sterile individually wrapped polystyrene pipets with aerosol barrier.
- Sterile centrifuge tubes, Corning.
- 1cc, 3cc, 10cc, 20cc, 30cc, and 60cc sterile syringes, Becton Dickinson.
- 18G blunt nose needles, Becton Dickinson.
- Teflon tissue culture bags, 1L, (270ml nominal capacity) and 7ml capacity, Fluoroseal.
- Plastic volume-limiting pinch clips.
- Sterile Luer-Lok Connector tubing and bottle top septums, Nalgene.

Reagents

- Culture Medium: Sterile GMP-grade X-Vivo 20 serum-free medium, BioWhittaker, Walkersville, MD
- Heparin: Preservative-free, Life Technologies.
- Dnase I: Roche Diagnostics. Reconstituted with sterile water and filtered through a
- Thawing Medium: X-Vivo 20 supplemented with 10 IU/ml heparin and 10µg/ml Dnase.
- rhuTPO, GMP grade, Pharmacia (previous sources for TPO and TPO-related growth factors were from R&D, Amgen, Searle).
- rhuIL-3, GMP grade, R&D Systems, Minneapolis, MN. 25 µg per vial, reconstituted with 250µl sterile PBS
- Flt-3L, GMP grade, Immunex Corp, Seattle WA. 250 µg per vial, reconstituted with 250µl sterile water
20µL aliquots of each cytokine stored at -70°C in sterile tubes until needed. Thawed aliquots of cytokines were kept at 4°C for up to two weeks.
- 1% Trypan Blue (Sigma) in saline.
- Phycoerythrin-cyanin 5.1 (PC5) conjugated-α-CD34, Clone 581, Beckman Coulter,
- Phycoerythrin (PE) conjugated -α-CD41 Clone P2, Beckman Coulter
- Fluorescein isothiocyanate (FITC) conjugated-α-CD15, Clone 80H5, Beckman Coulter
- Clonogenic assay kits for CFU-MK (MegaCult C) and CFU-GM (MethoCult), Stem Cell Technologies, Vancouver, BC, Canada
- Quantikine huTPO ELISA, R&D Systems

Specimen Requirement

- Cells from a ten liter leukapheresis to be selected for CD34+ cells using the Clinimacs system. The CD34+ purified cells were then frozen by the Bone Marrow Transplant laboratory using the standard cell freezing system.

Procedure

A. Sample Preparation

1. Frozen CD34+ cell tube placed into a resealable plastic bag. Close bag (to prevent any water seepage into tube).
2. The bag with the tube is then placed in a 37° water bath and gently agitated until the cell suspension has thawed to a small ball of ice (approximately 3-4 minutes per 5 ml tube).
3. The bag is wiped dry and transferred to a Class B sterile tissue culture hood.
4. In the sterile tissue culture hood, the contents of each tube of thawed cells is transferred to a sterile 50ml centrifuge tube using a sterile polypropylene transfer pipet and diluted 1:10 by drop-wise addition of

cold thawing medium using a sterile polypropylene transfer pipet with very gentle agitation/vortexing.

5. The tube is sealed and the cell suspension is centrifuged at 260xg for 10 min, 4°.
6. The cell pellet is resuspended in 2-3 ml X-Vivo 20 using a sterile polypropylene transfer pipet, then diluted to 50ml with X-Vivo 20 by decanting fresh medium. A 50µl sample for cell concentration analysis is taken using a sterile pipet tip with aerosol barrier. This sample is diluted 1:1 with Trypan Blue, applied to a hemacytometer, and the cell concentration and viability determined using a phase contrast microscope.
7. The cell suspension is centrifuged again at 260xg for 10 min at 4°. The cell pellet is resuspended in 2-3ml of X-Vivo 20 using a sterile polypropylene transfer pipet, then diluted with up to 20ml X-Vivo 20 by decanting fresh medium.

B. Culture Preparation

1. The final volume (FV) required to achieve a cell concentration of 400,000 cells/ml is calculated using the cell count obtained above in A.6.
 2. The bag's nominal volume is adjusted with bag clip barriers so as to contain a volume sufficient to suspend the cells at 400,000 c/ml at an average fluid height of 1cm.
 3. The cells are injected using a 20cc syringe into a 1L Teflon bag attached via Luer-Lok connections.
 4. X-Vivo 20 and sufficient cytokines to achieve a final concentration of 100ng/ml Flt-3L, 100ng/ml TPO and 10ng/ml IL-3 are then added using a 60cc syringe attached via Luer-Lok connections to the bag to reach the FV calculated in B.1.
 5. After gently agitating the bag to resuspend the cells, a 3ml aliquot is removed using a 10cc syringe. This is injected into a 7ml Teflon bag, adjusted with bag clip barriers so as to contain a volume sufficient to suspend the cells at an average fluid height of 1cm. This test sample is used to assay the culture progress and avoid opening the main sample bag until adjustment is necessary (See Sample Assays below). Both bags are stored in a 37° tissue culture incubator at 5% CO₂ and >90% relative humidity used solely for the purpose of clinical patient sample incubation.
1. Each day a 100µl of culture is removed from the test sample bag using a 1 ml syringe for cell concentration measurement. If the cell concentration is in excess of 800,000 c/ml, then a new bag clip barrier is placed on the bag so as to contain the new nominal volume required to dilute the cells to 400,000 cell/ml, and the old bag clip barrier is removed. The required volume of fresh X-Vivo 20 w/ cytokine

cocktail is added to the main sample using a 60cc sterile syringe attached via Luer-Lok connections to the bag. If the new total volume exceeds the 1cm liquid height capacity of the bag, a new bag is attached to the old bag via a Luer-Lok connector tube, and the sample is equally divided between the two bags by suspending the bags until the volumes are equilibrated by gravity. Bag clips are used to keep the volume height at the specified 1cm.

C. Sample Assays

The following assays are performed at the start and end of the culture: Samples are washed and stained for phenotypes CD34, CD41, and CD15 and analyzed by flow cytometry.

1. 100,000 cell aliquots are washed in 1% BSA (Sigma) in PBS (GIBCO) with 5mM EDTA (Sigma), designed to prevent further platelet activation and/or reverse adherence of activated platelets. The wash buffer is aspirated and the pellet resuspended in 50 μ l of PBS.
2. After washing, the cells are stained for 15 min at 4°C in the dark with 5 μ l of PC5-CD34, PE- α -CD41, and FITC- α -CD15 and analyzed by flow cytometry on the same day. The negative controls are PC5-, PE- and FITC- α -mouse IgG₁ used at equivalent IgG₁ concentrations. Only the non-apoptotic high forward scatter, low side scatter cell population was used for subset analysis.
3. Clonogenic assays are performed according to the manufacturer's instructions. Viable cells from each day of assay are seeded at a concentration of 10³ cells/ml. CFU-MK are scored after ten days and CFU-GM/BFU-E after fourteen days.
4. Twenty-four to forty-eight hours prior to the culture endpoint, a small aliquot of the patient cell culture is assayed for the following: Quantitative PCR for malignancies other than breast cancer and histochemistry for breast cancer cells. Sterility: Bacterial, viral, and fungal contamination, endotoxin titer, and mycoplasma levels.
5. When the designated culture period is reached, the sample bag(s) is(are) attached via Luer-Lok connector tubes to a cell washing bag and transfer to a COBE 2991 Cell Washer. Cells are prepared for transplant according to Bone Marrow Transplant Laboratory procedures.
6. A small aliquot of the buffer from each round of washed cells is assayed for residual TPO by ELISA, following manufacturers instructions, to monitor effectiveness of washing at removing cytokines from cell suspension.

Materials and Methods Used for Investigating the role of murine prolactin-like protein E on enhancing the expansion of human megakaryocytes in vitro:[7]

The PLP-E cDNA was linked in-frame to a secreted alkaline phosphatase (AP) gene in a mammalian expression vector. Fusion protein was obtained by transient transfection of the DNA construct into Chinese hamster ovary cells and subsequent collection of culture medium over a 2-day period. Medium containing secreted AP-PLP-E was concentrated and used in binding assays. PLP-E without the AP fusion partner was generated by similar approaches. Other methods described above.

Materials and Methods Used for Investigating the molecular mechanism of proplatelet formation:[8]

This investigation was carried out with the human CHRF-288 megakaryoblastic cell line.

Cell Culture: CHRF-288 cells were cultured in Fischer's medium supplemented with 20% fetal bovine serum as a source of growth factors and integrin ligands. To identify the serum factor responsible for MK differentiation, serum-free culture was carried out with X-vivo-20 medium in plates coated with various extracellular matrix proteins. PMA at 10 ng/ml was used to promote cell differentiation.

Ploidy analysis: Nonadherent cells were collected by centrifugation. Adherent cells were dislodged with 0.05% trypsin in 0.33 mM EDTA, and the viable cells counted by trypan blue exclusion. Then, 5X10E% cells per sample were washed in PBS containing 1% BSA. DNA was stained with 7-amino-actinomycin D following one-step fixation-permeabilization with the Ortho-Permafix reagent. Ploidy classes were then determined following flow cytometric analysis.

Protein extraction and Western Blot: Cells were collected after PMA treatment. Nonadherent and dislodged adherent cells were centrifuged at 400g for 5 min and the cell pellets lysed in a buffer containing 30 mM Hepes, 100 mM NaCl, 10 mM benzamidine, 1 mM EDTA, 1% Triton-X-100 and 20 mM NaF, adjusted to pH 7.5. The following protein and phosphatase inhibitors were then added: 1 mM phenyl methyl sulfonyl fluoride, 10 ug/ml aprotinin, 5 ug/ml leupeptin, 2 ug/ml pepstatin, 1 mM Na vanadate. Cell lysates were cleared by centrifugation at 16,000 rpm for 5 min at 4°C. Lysates were denatured by boiling for 5 min in Laemmli sample buffer and loaded at a concentration of 20 ug per lane on 10% Tris-glycine iGel. Antibodies against signal proteins or phosphorylated signal proteins were used to determine the activation of the kinases during cell differentiation. Each antibody was diluted in blocking buffer and incubated with the blot at room temperature for 2 hours, then incubated with alkaline phosphatase conjugate for 1 hour at room temperature and color detected by BCIP/NBT substrate liquid system.

Other methods described above.

Results:

1.Small Scale Culture using cytokine combinations from various corporate sources (year 01-03)[2, 3, 5, 9]

The combination of Promegapoietin/Progenipoietin (Searle) resulted in increased frequency of MK progenitors (CD34+/CD41+) from 3.2% a day 3 to 14-19% at day 3 (p<0.001). Cultures seeded at high density (HD, 4x10⁵ cells/ml) resulted in improved expansion of MK progenitors and differentiated MK when compared to low seeding

density (LD, 1×10^5 cells/ml) ($p < 0.001$). By day 13, MK expansion per CD34+ cell reached 745-fold in HD cultures, compared to 500-fold in LD cultures. The combination of MGDF/SCF (Amgen) induced similar expansion of MK progenitors and differentiated MK. Since MK maturity at the time of transplant may influence the rate of platelet engraftment, we evaluated this parameter by grouping CFU-MK colonies on the basis of four size populations. Immature CFU-MK were present at days 0 and 3 at levels of 45% and 27%, respectively, and dropped to less than 5% at day 6 and even less or non-existent at day 9. The time of cell harvest determines, therefore, the stage of MK differentiation. We then substituted TPO, IL-3 (R&D Systems) and Flt3-L (Immunex) for the former growth factors, after MGDF and SCF became unavailable. The combination of 100 ng/ml TPO and Flt3-L and 10 ng/ml IL-3 proved effective for expanding CD34+/CD41+ cells. After the lengthy procedure for obtaining approval of a revised protocol by the Army Human Subject Board, we submitted a proposal to the FDA for an IND pertaining to a clinical protocol.

2. Large Scale Culture (year 04-05) [5, 6]

CD34 cells were cultured under optimal conditions as determined by the small scale experiments with the use of 100 ng/ml TPO, 10 ng/ml IL-3, and 100 ng/ml Flt-3L. Up to 270 ml were cultured in 1 L Teflon bags and assayed daily for 9 days. Small scale cultures indicated that 9 days of culture was required for adequate progenitor cell expansion, while at 6 days there were still a significant proportion of early MK progenitors indicated as essential for platelet engraftment. Thus, analysis will focus on results at Day 6 and Day 9. Cell expansion and viability was measured (Figure 1). Viable cell expansion was found to drop during the first 1 to 2 days of culture, then begin expanding after 3 days. Starting at Day 6 began expanding rapidly. Total viable cells expanded 4.5-fold, with 64% viability after 6 days and 11.7-fold with 69% viability after 9 days. However, there was little improvement in total cell viability after Day 4.




Figure 1: A) Total cell expansion and B) overall cell viability. Cells were assayed daily for number and frequency of Trypan Blue-negative cells.

Progenitor cell expansion

Progenitor frequency was assayed and relative expansion was calculated (Figure 2). CD34+ cells declined to 59.9% of total cells at day 6 and 31.3% at day 9, but expanded

2.85-fold and 4.1-fold at day 6 and 9, respectively. Megakaryocyte progenitors comprised 13.2 and 13.4% of cells at day 6 and 9 respectively, and each seeded CD34⁺ cell produced 0.6 and 2.1 CD34⁺/CD41⁺ cells after 6 and 9 days in culture. Megakaryocytes comprised 17.2% and 39.9% of cells at day 6 and 9 respectively, and each seeded CD34⁺ cell produced 0.8 and 6.2 CD41⁺ cells after 6 and 9 days in culture.

Colony assays were performed after 3, 6 and 9 days and compared to seeded progenitors (Figure 3). CFU-GM and BFU-E colonies expanded over 9 days, and CFU-GEMM expanded slightly. CFU-MK numbers decreased at 3 days, then recovered by Day 9.




Fig. 2: Relative frequency and Expansion of CD34⁺, CD34⁺/41⁺, and CD41⁺ progenitor cells.




Fig. 3. Progenitor colony assay

3. Clinical Trial

Three patients were successfully transplanted. Patient NU97B2001 was transplanted with cells expanded using the cocktail of growth factors thrombopoietin and IL-3 from R&D and Flt3-L from Immunex at concentrations of 100 ng/ml, 10 ng/ml and 100 ng/ml, respectively. Platelet engraftment, defined as the day platelet count increases past 20,000/ μ l, occurred at day 6 post-transplant (26,000/ mm^3) (Fig. 4). While expanded cells for the next patient were in preparation, the FDA notified us to avoid using thrombopoietin from R&D because of concerns regarding the purification process. Transplantation was aborted for this patient. Thrombopoietin from Pharmacia was substituted for the R&D product for the other two transplanted patients. Platelet engraftment for patients NU97B2004 and NU97B2005 occurred at days 11 and 8. The data relative to the transplant of the three patients is described in Table 1.




Fig.4.

Two additional patients selected for using the ex-vivo expanded product did not receive it. In one case, the cell viability of 58% was below the allowed threshold of 70% and in the other case, the endotoxin test was positive.

Table 1. NU97B2 Patient Sample Results

Sample	NU97B2001	NU97B2002	NU97B2003	NU97B2004	NU97B2005	NU97B2006	Mean (n=6)
Culture Length (days)	6	9	9	6	6	6	7
Infusion Date	10/30/01	3/4/02	4/2/03	4/16/03	4/23/03	8/21/03	
Total Cells Seeded	1.04E+08	7.76E+07	5.11E+08	4.20E+08	8.61E+07	2.08E+08	2.34E+08
Total Cell Expansion (Fold)	7.6	2.2	2.5	2.8	3.9	4.0	3.8
Total Cells Infused	5.24E+08	1.71E+08	1.28E+09	1.07E+09	2.74E+08	5.67E+08	6.48E+08
Body Weight (Kg)	67.3	68.2	54.4	76.8	79.5	68.2	69.1
Cells infused/Kg	7.79E+06	2.51E+06	2.35E+07	1.40E+07	3.45E+06	8.31E+06	9.93E+06
Final CD34%	63.0%	34.0%	12.0%	43.9%	44.3%	80.4%	46.3%
CD34 Cell Expansion (Fold)	4.31	0.81	0.31	1.24	1.86	3.94	2.08
CD34 cells infused/Kg	4.91E+06	8.52E+05	2.82E+06	6.13E+06	1.53E+06	6.68E+06	3.82E+06
Final CD34/41%	30.0%	16.0%	6.0%	18.2%	16.7%	61.0%	24.7%
CD34/41 cells obtained per seeded CD34 cell	2.11	0.38	0.15	0.51	0.70	2.99	1.14
CD34/41 Cells Infused/Kg	2.34E+06	4.01E+05	1.41E+06	2.54E+06	5.76E+05	5.07E+06	2.06E+06
Final CD41%	35.2%	32.0%	27.0%	33.5%	44.6%	74.8%	41.2%
CD41 cells obtained per seeded CD34 cell	2.41	0.77	0.69	0.94	1.87	3.67	1.73
CD41 cells Infused/Kg	2.74E+06	8.02E+05	6.35E+06	4.68E+06	1.54E+06	6.22E+06	3.72E+06
Infused Cell Viability	70%	70%	58%	79%	78%	80%	73%
Bacterial Contamination	Neg	ND	ND	Neg	Neg	Neg	
Fungal Contamination	Neg	ND	ND	Neg	Neg	Neg	
Gram Stain	Neg	ND	ND	Neg	Neg	Neg	
Staph Endotoxin	Neg	ND	Neg	Neg	Neg	Pos	
Final Release Status	Infused	NOT infused	NOT infused	Infused	Infused	NOT infused	3/6
Mycoplasma	Neg	ND	ND	Neg	Neg	ND	
Malignant Contamination	Neg	ND	Neg	Neg	Neg	ND	
Time to 20k Plts (days)	7			12	13		11
Final Platelet Function	Normal	ND	ND	Normal	Normal	ND	
Anti-TPO Antibodies	ND	ND	ND	ND	ND	ND	
Residual TPO (ng/ml)	1.2	ND	0	1.8	0.3	0.8	0.82

ND = Not determined

4. Role of murine prolactin-like protein E on enhancing the expansion of human megakaryocytes in vitro.[7, Appendix 3]

PLP-E alone did not promote human MK differentiation, but instead synergized with TPO to increase colony-forming unit megakaryocyte (CFU-MK), burst-forming unit erythroid (BFU-E), and colony-forming unit granulocyte erythroid macrophage mixed (CFU-GEMM) expansion, as well as total MK production. These effects can be attributed to an increase in colony frequency combined with a significantly greater total cell expansion induced by adding PLP-E along with TPO. PLP-E significantly expanded immature, intermediate, and mature CFU-MK subsets at 3 days of culture, as well as the intermediate and mature subsets at day 6. PLP-E combined with TPO induced significant expansion of all CFU-MK subsets at all time points. PLP-E further increased the effect of SCF and Flt-3L on TPO-induced total cell and CFU-MK expansion. In conclusion, PLP-E may act as a survival factor for primitive human megakaryocytic and erythroid progenitors.

5. Molecular mechanism of proplatelet formation.[8, Appendix 4]

Proplatelet formations are precursors for platelet production (PPF). The megakaryoblastic CHRF-288 cell line was used to investigate the mechanism of PPF. The role of fibronectin (FN) and protein kinase C (PKC) were examined. In the presence of serum and phorbol 12-myristate 13-acetate (PMA), a PKC activator, cells exhibited full MK differentiation, manifested by adhesion, shape change, increased cell size, polyploidy, PPF, and expression of CD41+, CD61+ and CD62P+. The same morphologic and phenotypic features were observed in serum-free cultures in the presence of FN/PMA. FN alone induced minimal cell adhesion and spreading, while PMA alone induced only polyploidy without adhesion. Signal transduction changes involved the activation of extracellular signal-regulated protein kinase 1 (ERK1)/ERK2 as well as c-Jun amino-terminal kinase 1 (JNK1)/stress-activated protein kinase (SAPK). Phosphoinositide-3 kinase and p38 were not stimulated under these conditions. Inhibitors were used to identify the causal relationship between signaling pathways and PPF. PD98059 and GF109203X, inhibitors of ERK1/ERK2 pathway and PKC, respectively, blocked PPF, while adhesion, spreading and polyploidy were normal. These studies show that activation of ERK1/ERK2 mitogen-activated protein kinase pathway plays a critical role in PPF. The elucidation of the signal transduction pathway on megakaryocyte development and PPF is of crucial importance for understanding this unique biological process.

KEY RESEARCH ACCOMPLISHMENTS:

- The cocktail of growth factors (thrombopoietin/IL-3/Flt3-L) that optimally stimulates MK ex vivo expansion was identified.
- High density of cell seeding (4×10^5 cells/ml) yields higher expansion of MK as compared to low density (1×10^5 cells/ml) in both small-scale and large-scale cultures.
- Approval of IND (BB-IND 9559) by the FDA
- Successful platelet engraftment in three patients transplanted with ex vivo expanded MK.
- The Prolactin-Like Protein E (PLP-E) mediates human myeloid precursor survival and expansion. We have added a new effective product to the arsenal of cytokines to

be used in future *ex vivo* expansion protocols involving all human myeloid precursors, including MK.

- 9 Activation of ERK1/ERK2 mitogen-activated protein kinase pathway plays a critical role in proplatelet, formation which precedes platelet production.

Due to the pitfalls described in the introduction which were beyond our control, we were not able to transplant the number of patients mentioned in the Statement of Work. However, this study showed that using an *ex vivo* expanded product is feasible, and the successful outcome in our three transplanted patients augurs well for future use of this concept.

Although the last two points were not proposed in the original grant, since several months elapsed due to the withdrawal by pharmaceutical companies of various cytokines used in our project and the revision and approval time of revised protocols, we enriched the project with the data obtained, published in well-refereed journals.

REPORTABLE OUTCOMES:

Published Papers (attached in Appendix):

1. Lefebvre, P., Winter, J.N., Kahn, L.E., Giri, J.G., Cohen, I. Megakaryocyte *ex vivo* expansion potential of three hematopoietic sources in serum and serum-free medium. *J. Hematotherapy*, 8:199-208 (1999).
2. Lefebvre, P., Winter, J.N., Meng, Y., Cohen, I. *Ex vivo* expansion of early and late megakaryocyte progenitors. *J. Hematotherapy and Stem Cell Research*, 9:913-921 (2000)
3. Lefebvre, P., Lin, J., Linzer, D.I.H., Cohen, I. Murine prolactin-like protein E synergizes with human thrombopoietin to stimulate expansion of human megakaryocytes and their precursors. *Exp. Hematology*, 29:51-58 (2001)
4. Jiang, F., Jia, Y., Cohen, I. Fibronectin- and protein kinase C-mediated activation of ERK/MAPK are essential for proplateletlike formation. *Blood*, 99:3579-3584 (2002)
5. P Lefebvre and I Cohen. "Large Scale *Ex Vivo* Expansion of Human Megakaryocytes for Clinical Use." in Cytokines and Colony Stimulating Factors: Methods and Protocols Edited by D Körholz and W Kiess. Humana Press, Totowa NJ, 2003.

Paper in preparation to be submitted to Cytotherapy:

Lefebvre, P., Winter, J.N., Cohen, I. Scale up and transplant of *ex vivo* expanded megakaryocyte progenitors using rhTPO, IL-3 and Flt-3L

Abstracts at Scientific Meetings:

1. Lefebvre, P., Meng, Y.R.I., Miller, W.M., Rademaker, A., Papoutsakis, T., Minster, N., Baum, C.M., McKearn, J.P., Winter, J.N., Cohen, I. Increased megakaryocyte expansion with promegapoietin-progenipoietin combination and high seeding density. ASH meeting, Miami, 1998. *Blood* 92, Suppl. 1, 1998 (Abstract 2671)

2. Lefebvre, P., Lin, J., Linzer, D.I.H., Cohen, I. A novel murine pregnancy-specific hormone acts as a multilineage survival factor for human bone marrow progenitors. ASH meeting, New Orleans, 1999. Blood 94, Suppl,1, 1999 (Abstract 837)
3. Lefebvre, P., Winter, J.N., Meng, Y., Cohen, I. Expansion of early and late megakaryocyte progenitors using MGDF, SCF and G CSF in a defined-serum medium. ASH meeting, New Orleans, 1999. Blood 94, Suppl, 1999 (Abstract 4783)
4. Jiang, F., Cohen, I. Fibronectin- and protein kinase C-mediated activation of p42/44 mitogen-activated protein kinase are essential for proplatelet formation. San Francisco, 2000. Blood, Suppl. 2000 (Abstract 328).
5. Cohen, I., Jiang, F. Fibronectin- and protein kinase C-mediated activation of ERK/MAPK are essential for proplateletlike formation. XVIIIth Cong. of the Int. Soc. on Thrombosis and Haemostasis, Paris, 2001

CONCLUSIONS:

The results from the three transplanted patients were positive and encouraging. Cell expansion was optimal after 6 days of culture, no negative reactions were observed, and the patients recovered normal platelet levels fast, with normal platelet function. For reasons beyond our control we were not able to transplant the number of patients cited in the Statement of Work, however, this study shows that using an *ex vivo* expanded product is feasible and the successful outcome in our three transplanted patients augurs well for future use of this concept.

Additionally, we have added a novel survival factor, PLP-E, to the arsenal of cytokines used for *ex vivo* myeloid expansion, including megakaryocytes, and have elucidated a signaling mechanism critical for proplatelet formation.

PERSONNEL RECEIVING PAY:

Isaac Cohen, Ph.D.

Jane N. Winter, MD

Yuru Meng, MD

Fang Jiang, MD

Phil Lefebvre, M.Sc.

REFERENCES:

1. Webb, I.J. and K.C. Anderson, *Risks, costs, and alternatives to platelet transfusions [Review]*. Leukemia & Lymphoma, 1999. 34(1-2): p. 71-84.
2. Lefebvre, P., et al., *Increased Megakaryocyte Expansion With Promegapoietin-progenipoietin Combination And High Seeding Density*. Blood, 1998. 92(Suppl): p. 647a.
3. Lefebvre, P., et al., *Ex vivo expansion of early and late megakaryocyte progenitors*. J Hematother Stem Cell Res, 2000. 9(6): p. 913-21.
4. Nichol, J.L., et al., *Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia*. J Clin Invest, 1995. 95(6): p. 2973-8.
5. Lefebvre, P., J.N. Winter, and I. Cohen, *Scale Up and transplant of ex vivo-expanded human megakaryocyte progenitors using rhTPO, IL-3, and Flt-3L*. Cytotherapy, 2003. To be submitted.
6. Lefebvre, P. and I. Cohen, *Large-scale ex vivo expansion of human megakaryocytes for clinical use*. Methods Mol Biol, 2003. 215: p. 375-85.
7. Lefebvre, P., et al., *Murine prolactin-like protein E synergizes with human thrombopoietin to stimulate expansion of human megakaryocytes and their precursors*. Exp Hematol, 2001. 29(1): p. 51-8.
8. Jiang, F. and I. Cohen, *Fibronectin- and Protein Kinase C-Mediated Activation of Erk1/2 MAPK Are Essential For Proplatelet-Like Formation*. Blood, 2002. 99(10): p.3579-3584.
9. Lefebvre, P., et al., *Megakaryocyte ex vivo expansion potential of three hematopoietic sources in serum and serum-free medium*. J Hematother, 1999. 8(2): p. 199-208.

Appendix I

JOURNAL OF HEMATOTHERAPY 8:199-208 (1999)
Mary Ann Liebert, Inc.

Megakaryocyte Ex Vivo Expansion Potential of Three Hematopoietic Sources in Serum and Serum-Free Medium

PHIL LEFEBVRE,¹ JANE N. WINTER,² LARRY E. KAHN,³ JUDITH G. GIRI,³
and ISAAC COHEN¹

ABSTRACT

Megakaryocytes (MK) were expanded from purified human CD34⁺ cells obtained from three sources, bone marrow (BM), mobilized peripheral blood progenitor cells (PB), and umbilical cord (UC) blood. CD34⁺-selected cells were cultured for 12 days with 10 ng/ml thrombopoietin (TPO), 10 ng/ml IL-3, 10 ng/ml TPO + 10 ng/ml IL-3, or 200 ng/ml promegapoietin (PMP), a chimeric dual agonist of the c-Mpl and human IL-3 receptors. MK production was compared in serum-free versus human serum-supplemented liquid media. PMP and the combination of TPO and IL-3 (TPO + IL-3) increased MK production similarly. Culturing CD34⁺ cells with PMP in serum-free medium resulted in a twofold increase in MK yield compared with serum-supplemented medium. CD34⁺ cells from UC proliferated more than those from either BM or PB in liquid culture, resulting in much greater MK production under all conditions. Phenotypic analysis of the uncultured CD34⁺ cells showed that BM had a higher frequency of CD34⁺/CD41⁺ cells than PB or UC. TPO + IL-3 or PMP produced larger and greater numbers of BFU-MK and CFU-MK per seeded CD34⁺/CD41⁺ cell from UC than from either BM or PB. Thus, although uncultured CD34⁺-selected BM cells contained a higher frequency of committed mature MK progenitors, UC CD34⁺ cells had a greater proliferative capacity and, therefore, were more productive. PMP induced megakaryocytopoietic activity comparable to that achieved with TPO + IL-3 and may be useful for ex vivo expansion of MK for clinical trials.

INTRODUCTION

HEMATOPOIETIC PROGENITOR CELL TRANSPLANTS in which bone marrow (BM), mobilized peripheral blood progenitor cells (PB), or umbilical cord (UC) blood is used to reconstitute hematopoiesis following high-dose chemotherapy is associated with a requisite period of profound thrombocytopenia (1-4). One theoretic approach to shortening the period of thrombocytopenia in patients undergoing autologous PB transplantation is to increase the mobilization of megakaryocyte (MK) progenitors using specific cytokines. The cloning of thrombopoietin (TPO) and its reported activity on all phases of megakary-

ocytopoiesis and thrombopoiesis (5-11) have raised the possibility of its clinical use for this purpose. However, in view of the restricted pool of stem cells in patients who have received prior chemotherapy, it is often difficult to mobilize adequate numbers of progenitors with the use of cytokines. Experimental studies in rhesus monkeys have shown that TPO administration is ineffective when TPO target cells are reduced by high-dose irradiation (12). Another alternative approach to shortening the period of thrombocytopenia is to administer TPO after transplant to thrombocytopenic patients, although this strategy may be ineffective in raising platelet counts in view of the high levels of endogenous TPO already cir-

¹Department of Cell and Molecular Biology and ²Department of Medicine, Northwestern University, Chicago, IL 60611.

³Searle Research and Development, Monsanto Co., St. Louis, MO 63198.

culating in the PB of these patients (13). Supplementing conventional transplants with an MK-rich product may provide an alternate approach to enhancing *in vivo* platelet production and shortening the period of thrombocytopenia. This was proven effective in one animal study using mice (14). In a clinical trial in which 10 patients received *ex vivo* expanded MK, 2 of the 4 patients receiving the highest numbers of MK did not require platelet transfusions (15).

TPO has been used in combination with a variety of cytokines to increase the yield of MK in liquid cultures (16–20). Human BM CD34 cells cultured in the presence of TPO and IL-3 produced over threefold more MK than with TPO alone (18). However, IL-3 is not available for clinical use in the United States. Thus, we investigated the megakaryocytopoietic effect of promegapoeitin (PMP, G.D. Searle Co., St. Louis, MO), a chimeric dual agonist of both the c-Mpl and human IL-3 receptors (21), to see if it could generate sufficient numbers of MK *in vitro* for use as a supplement to conventional stem cell autografts. It was reported previously that PMP is superior to TPO or IL-3 alone and comparable to TPO + IL-3 in stimulating *in vitro* megakaryocytopoiesis in human BM (22). Moreover, experimental studies in nonhuman primates showed that a single dose of PMP hastens the time of platelet recovery (23). In this study, the megakaryocytopoietic capacity of PMP is compared with TPO ± IL-3 using CD34⁺-selected cells from human BM, UC blood, and PB. Cells were cultured in a serum-containing medium and compared with serum-free medium for the *ex vivo* expansion of MK.

MATERIALS AND METHODS

Preparation of low-density nonadherent mononuclear cells (MNC)

All samples were collected within the guidelines of the Northwestern University Institutional Review Board on Human Subjects. BM, obtained from the femur of hematologically normal patients having total hip arthroplasty, was collected in anticoagulant designed to prevent platelet activation and containing final concentrations of 50 U/ml preservative-free heparin (GIBCO/Life Technologies, Gaithersburg, MD), 1 mM Na₂ EDTA, 1 mM adenosine, 2 mM theophylline, 2.2 μM prostaglandin E₁ (PGE₁) (Sigma Co., St. Louis, MO), and 0.1 mg/ml DNase I (Boehringer Mannheim, Indianapolis, IN) in 20 ml alpha-modified Eagle's medium (α-MEM, Sigma). BM cells were repeatedly extracted from bone fragments with α-MEM containing 100 U/ml penicillin, 100 μg/ml streptomycin (Boehringer Mannheim), 0.1 mg/ml DNase I (Boehringer Mannheim), and 4 μg/ml gentamicin (Life Technologies). The extract was homogenized by passage

through a 21-gauge needle to remove bone fragments. UC blood samples were collected after cesarean section from the freshly delivered placentas of full-term, healthy newborn infants into a 50 ml tube containing 5 ml of anticoagulant without DNase. The blood was diluted 1:1 with α-MEM. BM and UC low-density MNC were isolated with the use of Ficoll-Paque (Pharmacia Corp., Piscataway, NJ) as described (24). PB was collected by continuous flow apheresis from cancer patients destined for high-dose chemotherapy and autologous transplant, following mobilization with G-CSF. PB was cryopreserved in FBS (GIBCO) with 10% DMSO and stored at –120°C until needed (up to 3 months) (25). Ampules were thawed rapidly in a 37°C waterbath and transferred to a thawing medium of α-thioglycerol-free IMDM (GIBCO) containing 20% FBS, 12.5 μg/ml DNase I, 12.5 U/ml heparin, 100 μM Dulbecco's modified Eagle's nonessential amino acids (NEA, GIBCO), 100 U/ml penicillin, and 100 μg/ml streptomycin at 4°C and kept on ice for 15–30 min, then centrifuged at 260g for 10 min. Cells were resuspended in α-MEM containing 1% human serum albumin (HSA) (Baxter Hyland, Deerfield, IL) and centrifuged at 380g through a 10% HSA cushion in PBS to reduce platelet contamination. Residual red cells were lysed with NH₄Cl (Sigma) as described (26), and the remaining cells were recovered by centrifugation for 6 min at 420g through a 10% HSA cushion. Adherent cells from BM, UC, and PB were discarded after overnight incubation at 37°C in a 5% CO₂, fully humidified atmosphere in IMDM containing 10% FBS supplemented with 100 μM NEA, 4 μg/ml gentamicin, 100 U/ml penicillin, and 100 μg/ml streptomycin.

Purification of CD34⁺ cells

CD34⁺ cells were purified using magnetic cell sorting (27) (Mini-MACS kit, Miltenyi Biotec, Auburn, CA) following the manufacturer's recommendations. Cells were passed over two columns and eluted with IMDM. Over 90% of cells were viable with the use of the trypan blue exclusion test, and average purity was 85.2% ± 3.7% as assessed by flow cytometry.

Culture conditions

Cultures from three donors each of BM, PB, and UC were performed. For each cytokine combination, 5 × 10⁴ CD34⁺ cells were cultured in 1 ml of either IMDM containing 1% HSA and 2.5% pooled normal human serum or commercially available serum-free medium (Easymega, Hemeris, Sassenage, France). Human serum was obtained by recalcification of citrated platelet-free plasma (18) to prevent the inhibitory effects on MK growth of transforming growth factor-β (TGF-β), β-thromboglobulin, and platelet factor 4 released from ac-

tivated platelets (28–30). Cultures were supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin, and gentamicin (Life Technologies) and maintained for 12 days at 37°C in a 5% CO₂ fully humidified atmosphere. TPO (Zymogenetics Corp., Seattle, WA) (31) was used at a concentration of 10 ng/ml, which yielded the maximal concentration of MK. IL-3 (R&D Systems, Minneapolis, MN) was used at 10 ng/ml. PMP was used at 200 ng/ml. These concentrations were found optimal in earlier dose-response assays (data not shown). One volume of complete culture medium was added at day 6 if excessive cell growth ($>5 \times 10^5$ /ml) was observed. After 12 days, cultures were collected, and cells were counted in the presence of trypan blue. Only viable cells were counted and used for calculating MK production.

Clonogenic assay

Clonogenic assays using a serum-free collagen assay (32) (Easymega) were performed according to the manufacturer's instructions. The cytokines used were TPO 10 ng/ml or IL-3 10 ng/ml, or both, or PMP 200 ng/ml. CFU-MK were scored 8 days and BFU-MK were scored 14 days after fixation with methanol/acetone (1:1) and immunostaining with a cocktail of monoclonal anti-GPIIb (SZ2-IgG1) and anti-GPIIb (SZ22-IgG1) antibodies (Coulter/Immunotech, Westbrook, ME). Binding of rabbit antimouse IgG was revealed with an APAAP/substrate kit (Dako, Carpinteria, CA).

Flow cytometric analysis

For determination of CD34⁺ cell purity, up to 2.5×10^5 CD34 cells were treated with 200 pkat chymopapain (Knoll Pharmaceutical Co., Lincolnshire, IL) to detach platelet fragments and eliminate nonspecific GPIIb/IIIa attached to CD34⁺ cell surfaces (33). For analysis of MK progenitors (CD34⁺/CD41⁺), cell aliquots were washed in phosphate-buffered albumin (sPBA) designed to prevent platelet activation and containing 13.6 mM sodium citrate·2H₂O, 11 mM dextrose, 1 mM theophylline, 2.2 μ M PGE₁, and 10% BSA (Sigma) in Dulbecco's PBS, pH 7.4. After washing, the cells were stained for 15 min on ice in the dark with PE-conjugated- α -CD34 (HPCA-2, Becton, Dickinson, San Jose, CA) and FITC- α -CD41 (Coulter/Immunotech) and analyzed by flow cytometry. The negative controls were PE- and FITC- α -mouse IgG1 used at equivalent IgG1 concentrations. The relative frequency of mature MK was measured after 12 days in culture by flow cytometric analysis of cells stained with FITC- α -CD41a. Cells were washed again in sPBA and fixed with 1% paraformaldehyde (Ted Pella, Redding, CA) containing 0.067 M sodium cacodylate (Sigma) in saline. Flow cytometric analysis was performed using a

Coulter Cytometry XL (Coulter Co., Hialeah, FL) flow cytometer. Fluorescence attributable to FITC-labeled and PE-labeled antibodies was determined using excitation by an argon laser operating at 488 nm. Emissions from FITC and PE were measured using band pass filters of 525 nm and 585 nm, respectively. Approximately 10,000 events were counted per acquisition. The integration region for the CD34⁺ cells was set around the uppermost positive population of cells. The integration region for the CD41⁺ cells was set at 1% of the negative population. The percent positive cells was calculated by subtracting the percent positive of the isotype control within the same integration region.

RESULTS

Evaluation of culture media

BM CD34⁺ cells were cultured with 200 ng/ml PMP in serum-free medium, and total production of MK was compared with that obtained by culturing cells from the same donor in IMDM with 2.5% human serum (Fig. 1). Compared with human serum-containing medium, incubation in serum-free medium resulted in increased MK frequency and cell proliferation.




FIG. 1. MK productivity in the presence of serum-free medium. MK productivity was calculated on the basis of the relative frequency of MK and the total number of trypan blue-negative cells. Using PMP, serum-free medium (Easymega) produced more MK than did serum-containing medium.

Total cell proliferation

UC-derived CD34⁺ cells had higher total cell proliferation than either BM or PB under all conditions, whereas there were no differences between BM and PB (Fig. 2). In serum-containing medium, IL-3 induced greater cell proliferation than TPO for BM and PB but not UC, and combining TPO with IL-3 led to a cooperative increase in cell proliferation compared with TPO alone and IL-3 alone (Fig. 2A). In the same culture conditions containing UC cells, the proliferative effect of

PMP or TPO + IL-3 was additive compared with TPO or IL-3 alone. For UC, TPO + IL-3 induced greater cell proliferation than PMP in the presence of serum (Fig. 2A), whereas the inverse was true in serum-free medium (Fig. 2B).

Relative frequency of ex vivo expanded megakaryocytes

For each hematopoietic source, the percentage of CD41⁺ cells was greater in PMP, TPO, and TPO + IL-




FIG. 2. Total cell proliferation. The number of trypan blue-negative cells per milliliter of culture was counted for each sample. The mean \pm SEM total cell proliferation is shown. (A) Cells cultured in serum-containing medium. (B) Cells cultured in serum-free medium.

MK EXPANSION FROM BM, UC, AND PB

3-supplemented cultures when compared with IL-3-supplemented cultures in serum-containing medium (Fig. 3A). In these culture conditions, PMP induced a lower CD41⁺ cell frequency than did TPO alone (Fig. 3A). When BM cells were cultured in serum-free medium, TPO induced lower CD41⁺ cell frequencies than either TPO + IL-3 or PMP (Fig. 3B). Cultured BM and UC cells exhibited higher CD41⁺ cell frequencies than PB for all cytokine and culture medium combinations.

Total MK production

Overall, using either TPO + IL-3 or PMP resulted in greater MK production compared with TPO or IL-3 alone (Fig. 4). The addition of IL-3 to TPO cooperatively increased MK production for BM and PB compared with using TPO or IL-3 alone (Fig. 4A). The same cooperativity was seen with PMP. For UC in the presence of serum, the effect of TPO + IL-3 or PMP was additive




FIG. 3. Frequency of MK in culture. The mean \pm SEM %CD41⁺ for each sample is shown, as measured by flow cytometry. (A) Cells cultured in serum-containing medium. (B) Cells cultured in serum-free medium.

compared with TPO or IL-3 alone. UC cultures produced greater numbers of MK than BM or PB under all conditions (Fig. 4), and BM produced more MK than PB. Higher numbers of UC MK were obtained with TPO + IL-3 when compared with PMP in the presence of serum, and the inverse occurred in serum-free medium.

Clonogenic capacity of CD34⁺ cells

There were no differences between TPO + IL-3 and PMP in the number of either CFU-MK or BFU-MK colonies produced from any cell source (Table 1). Samples cultured with either TPO + IL-3 or PMP showed an




FIG. 4. Total number of MK produced for each condition. The mean \pm SEM number of MK, calculated by multiplying the total cell number by the MK frequency, for each sample is shown. (A) Cells cultured in serum-containing medium. (B) Cells cultured in serum-free medium.

MK EXPANSION FROM BM, UC, AND PB

TABLE 1. CLONOGENIC CAPACITY OF CD34⁺ CELLS^a

Cell source	CFU-MK		BFU-MK	
	PMP	TPO/IL-3	PMP	TPO/IL-3
UC (n = 5)	157 ± 26	149 ± 13	133 ± 39	109 ± 20
BM (n = 5)	84 ± 29	88 ± 23	47 ± 11	39 ± 10
PB (n = 5)	27 ± 4	32 ± 2	12 ± 2	11 ± 1

^aTotal number of colonies measured ± SEM. Each sample was analyzed in duplicate.

additive increase in the number of CFU-MK and BFU-MK when compared with samples exposed to TPO alone or IL-3 alone (data not shown). UC CD34⁺ cells produced more CFU-MK and BFU-MK colonies than did BM or PB cells (Table 1). The size of BFU-MK from UC (>200 cells per colony) was larger than the equivalent colonies from BM or PB (data not shown). In separate experiments, the frequency of MK progenitors (CD34⁺/CD41⁺) in the initial CD34⁺ cell population was measured by flow cytometry. CD34⁺/CD41⁺ cell frequency was greater for BM than for the other two hematopoietic sources (Table 2). There was no difference between UC and PB CD34⁺/CD41⁺ cell frequency. When the ratio of CFU-MK or BFU-MK colonies per seeded CD34⁺/CD41⁺ cells was calculated, UC cells produced a higher ratio than either BM or PB (Table 2).

DISCUSSION

In this study, we investigated whether PMP, a novel chimeric cytokine, could substitute for the combination of TPO and IL-3 in ex vivo expansion of MK and provide sufficient numbers for use as a supplement to stem cell transplants. PMP had comparable in vitro biologic activity to TPO + IL-3, and the serum-free medium we tested was superior to human serum-containing medium in supporting megakaryocytopoiesis.

Both PMP and TPO + IL-3 cooperatively increased MK production compared with either TPO or IL-3 alone

in both BM and PB liquid cultures. The data show that TPO exerts its megakaryocytopoietic effect by increasing the frequency of CD41⁺ cells in culture, whereas IL-3 increases total cell proliferation, particularly in BM and PB. In the more proliferative UC CD34⁺ cells, the effects of TPO and IL-3 were nearly equivalent. IL-3 is known to stimulate megakaryocytopoiesis independently of TPO (34,35), and combining TPO and IL-3 cooperatively increases megakaryocytopoiesis, as previously shown (16–19). This cooperativity may be because TPO and IL-3 can transmit some of their mitogenic signal through different cell signaling pathways (36–38) and amplify each other's signals. The design of PMP, a chimeric protein that activates both the c-Mpl and IL-3 receptors, can take advantage of these overlapping signal transduction pathways (39,40).

Depending on the cytokine combination used, the composition of the culture medium greatly affects MK production. In this respect, UC cells were more sensitive to PMP in serum-free than in serum-containing medium. The inverse was true for the combination of TPO and IL-3. The specific effect of components of culture medium, such as cannabinoid ligands, present in serum was reported recently (41). It was surmised that they affect cell production by transactivation of hematopoietic receptors, potentiation of signal transduction mediated by hematopoietic receptors, or activation of signalling pathways that enhance cell cycling in parallel with hematopoietic receptor transduction pathways. Moreover, in view of the different topography of their receptors, different

TABLE 2. MK COLONIES DERIVED FROM MK PROGENITORS^a

Cell source	%CD34 ⁺ /CD41 ⁺ ±SEM (n)	CFU-MK per CD34 ⁺ /CD41 ⁺ cell ±SEM (n)	BFU-MK per CD34 ⁺ /CD41 ⁺ cell ±SEM (n)
UC	1.8% ± 1.1% (22)	4.5 ± 0.7 (18)	3.1 ± 0.4 (18)
BM	4.0% ± 1.8% (19)	1.0 ± 0.1 (26)	0.4 ± 0.1 (21)
PB	1.6% ± 1.5% (23)	1.6 ± 0.3 (20)	0.7 ± 0.2 (12)

^aResults are for colonies cultured with TPO + IL-3. % CD34⁺/CD41⁺ determined by flow cytometry. CFU-MK and BFU-MK per CD34⁺/CD41⁺ cell was calculated by dividing the number of colonies by the number of CD34⁺/CD41⁺ cells seeded.

hematopoietic sources may not be equivalent in signalling pathways. These considerations may explain the different responses of cytokine combinations depending on the culture medium and the hematopoietic source used.

The increased frequency and production of CD41⁺ cells in BM as compared with PB were proportional to the CD34⁺/CD41⁺ frequency in the initially seeded population. Although UC cells had fewer CD34⁺/CD41⁺ cells, they were more proliferative than BM or PB cells. This led to greater MK production in UC cultures compared with PB or BM cultures. This may be because UC has a higher frequency of highly proliferative primitive progenitors (42,43). Results of clonogenic assays showed that UC produced more CFU-MK and BFU-MK colonies than the other two hematopoietic sources. In addition, these colonies were much larger in cell number, and the size and number of colonies were proportional to the proliferative potential of the cells, as previously reported (44). Interestingly, whereas BM and PB produced about as many colonies as there were MK progenitors (CD34⁺/CD41⁺ cells) in the initial seeded cell population, UC cells produced 4.5-fold and 3-fold more CFU-MK and BFU-MK, respectively, than the initial number of seeded MK progenitors would predict. This suggests that the more primitive UC CD34⁺ cells may be more easily recruited to the MK lineage by a c-Mpl ligand and would, therefore, generate more MK in culture.

Using a cocktail of seven cytokines, including MIP-1 α , IL-3, IL-6, IL-11, Flt-3L, SCF, and MGDF, in their ex vivo expansion protocol, Bertolini et al. (15) transplanted an enriched MK product into patients (15). Two of the four patients who received the highest MK infusions ($2.5\text{--}21.3 \times 10^5$ CD61⁺ cells/kg) did not require platelet transfusions. Our goal is to transplant a minimum of 21.3×10^5 MK/kg in the patient. Whereas Bertolini et al. (15) were able to harvest an average of 4.1 MK per cell seeded, we have shown that PB CD34⁺ cells cultured in serum-free medium with a single chimeric cytokine, PMP, will generate an average of 6.4 MK per cell seeded. Based on these figures, for a 70 kg patient, 2.3×10^7 CD34⁺ cells should be cultured for 12 days to reach our goal, well within technical and clinical limits. BM cells were twice as productive and UC cells 8.5-fold more productive as PB, further reducing the starting material required.

In conclusion, it is feasible to expand MK from human CD34⁺ cells ex vivo, producing a cellular product that could have important clinical use. Although UC cells were the most productive hematopoietic source on a per volume basis because of their high concentration of primitive progenitors, the MK yield observed with PB will be more than sufficient for clinical use. These preclinical studies demonstrate that the single chimeric cytokine PMP should yield sufficient numbers of MK for clinical trials, avoiding the difficulties associated with the use of

cytokines not approved for clinical use and with multiple corporate sources.

ACKNOWLEDGMENTS

This work was supported in part by a grant from the U.S. Army Medical Research and Material Command (DAMD 17-94-J-4465) and the Rehabilitation Institute of Chicago. We thank Dr. Donald Foster (Zymogenetics, Seattle, WA) for supplying TPO and Dr. Richard L. Wixson (Orthopedics Associates, Chicago, IL) for the availability of BM samples.

REFERENCES

1. Kessinger A, JO Armitage, JM Landmark, et al. (1988). Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. *Blood* 71:723, 1988.
2. Williams SF, JD Bitran, JM Richards, et al. (1990). PB-derived stem cell collections for use in autologous transplantation after high-dose chemotherapy: an alternative approach. *Bone Marrow Transplant* 5:129.
3. Takamatsu Y, M Harada, T Teshima, et al. (1995). Relationship of infused CFU-GM and CFU-MK mobilized by chemotherapy with or without G-CSF to platelet recovery after autologous blood stem cell transplantation. *Exp Hematol* 23:8.
4. Anderlini P, and M Korbling. (1997). The use of mobilized PB stem cells from normal donors for allografting. *Stem Cells* 15:9.
5. Bartley TD, J Bogenberger, P Hunt, et al. (1994). Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. *Cell* 77:1117.
6. de Sauvage FJ, PE Hass, SD Spencer, et al. (1994). Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. *Nature* 369:533.
7. Kaushansky K, S Lok, RD Holly, et al. (1994). Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. *Nature* 369:568.
8. Kuter DJ, DL Beeler, and RD Rosenberg. (1994). The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. *Proc Natl Acad Sci USA* 91:11104.
9. Lok S, and DC Foster. (1994). The structure, biology and potential therapeutic applications of recombinant thrombopoietin. *Stem Cells* 12:586.
10. Wendling F, E Maraskovsky, N Debili, et al. (1994). cMpl ligand is a humoral regulator of megakaryocytopoiesis. *Nature* 369:571.
11. Kato T, K Ogami, Y Shimada, et al. (1995). Purification and characterization of thrombopoietin. *J Biochem* 118: 229.
12. Neelis KJ, L Qingliang, GR Thomas, et al. (1997). Prevention of thrombocytopenia by thrombopoietin in myelo-

- suppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. *Blood* 90:58.
13. Shimazaki C, T Inaba, H Uchiyama, et al. (1997). Serum thrombopoietin levels in patients undergoing autologous PB stem cell transplantation. *Bone Marrow Transplant* 19:771.
14. Ratajczak M, J Ratajczak, B Machalinski, et al. (1997). In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia. *Blood* 91:353.
15. Bertolini F, M Battaglia, P Pedrazzoli, et al. (1997). Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral progenitor cell transplant recipients. *Blood* 89:2679.
16. Debili N, F Wendling, A Katz, et al. (1995). The Mpl ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. *Blood* 86:2516.
17. Young JC. (1996). Thrombopoietin stimulates megakaryocytopoiesis, myelopoiesis, and expansion of CD34⁺ progenitor cells from single CD34⁺Thy-1⁺Lin⁻ primitive progenitor cells. *Blood* 88:1619.
18. Schattner M, P Lefebvre, SS Mingolelli, et al. (1996). Thrombopoietin-stimulated ex vivo expansion on human BM megakaryocytes. *Stem Cells* 14:207.
19. Angchaisuksiri P, P Carlson, and E Dessypri. (1996). Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34⁺ cells in a serum-free system. *Br J Haematol* 93:13.
20. Dolzhanskiy A, RS Basch, and S Karparkin. (1997). The development of human megakaryocytes: III. Development of mature megakaryocytes from highly purified committed progenitors in synthetic culture media and inhibition of thrombopoietin-induced polyploidization by interleukin-3. *Blood* 89:426.
21. Giri J. (1996). Promegapoeitins: engineered growth and differentiation factors for platelet-producing cells. IBC Conference on Therapeutic Applications of Cytokines, Philadelphia, PA, p 441.
22. Kahn L, N Staten, D Wood, et al. (1996). Development of engineered hematopoietic growth factors for multilineage expansion and maturation of CD34⁺ progenitors. *Exp Hematol* 24:1071a.
23. Giri J, W Smith, L Kahn, et al. (1997). Promegapoeitin, a chimeric growth factor for megakaryocyte and platelet restoration. *Blood* 90 (Suppl 1):2583a.
24. Debili N, E Hegyi, S Navarro, et al. (1991). In vitro effects of hematopoietic growth factors on the proliferation, endoreplication, and maturation of human megakaryocytes. *Blood* 77:2326.
25. Winter J, H Lazarus, A Rademaker, et al. (1996). Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. *J Clin Oncol* 14:277.
26. Terstappen LW, M Safford, and MR Loken. (1990). Flow cytometric analysis of human BM. III. Neutrophil maturation. *Leukemia* 4:657.
27. Miltenyi S, W Muller, W Weichel, et al. (1990). High gradient magnetic cell separation with MACS. *Cytometry* 11:231.
28. Mitjavilla M, G Vinci, and J Villval. (1988). Human platelet alpha granules contain a non-specific inhibitor of megakaryocyte colony formation. *J Cell Physiol* 134:93.
29. Gewirtz A, B Calabretta, B Rucinski, et al. (1989). Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic C-terminal PF-4 peptide. *J Clin Invest* 83:1477.
30. Abgrall J, Z Han, L Sensebe, et al. (1991). Inhibitory effect of highly purified platelet β -thromboglobulin on in vitro human megakaryocyte colony formation. *Exp Hematol* 19:202.
31. Foster DC, CA Sprecher, FJ Grant, et al. (1994). Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. *Proc Natl Acad Sci USA* 91:13023.
32. Dobo I, A Allegraud, M Navenot et al. (1995). Collagen matrix: an attractive alternative to agar and methylcellulose for the culture of hematopoietic progenitors in autologous transplantation products. *J Hematother* 4:281.
33. Debili N, F Wendling, and D Cosman. (1995). The mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. *Blood* 85:391.
34. Debili N, JM Masse, A Katz, et al. (1993). Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34⁺ cells. *Blood* 82:84.
35. Kaushansky K, VC Broudy, N Lin, et al. (1995). Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. *Proc Natl. Acad Sci USA* 92:3234.
36. Dorsch M, PD Fan, J Bogenberger, et al. (1995). TPO and IL-3 induce overlapping but distinct protein tyrosine phosphorylation in a myeloid precursor cell line. *Biochem Biophys Res Commun* 214:424.
37. Mu S, M Xia, G Elliott, et al. (1995). Megakaryocyte growth and development factor and interleukin-3 induce patterns of protein-tyrosine phosphorylation that correlate with dominant differentiation over proliferation of mpl-transfected 32D cells. *Blood* 86:4532.
38. Broudy V, N Lin, N Fox, et al. (1996). Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit. *Blood* 88:2026.
39. Giri JG, LE Kahn, PD Doshi, et al. (1996). Promegapoeitin, an engineered chimeric growth factor for platelet producing cells. *Blood* 88 (Suppl 1):1393a.
40. Doshi PD, MS Huynh, JP Favara, et al. (1996). Induction of early gene expression by a chimeric cytokine with agonistic activities for human IL-3 and c-mpl receptors. *Blood* 88:786.
41. Valk P, S Verbakel, Y Vankan, et al. (1997). Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. *Blood* 90:1448.
42. De Bruyn C, A Delforge, D Bron, et al. (1995). Compari-

- son of the coexpression of CD38, CD33 and HLA-DR antigens on CD34⁺ purified cells from human UC and BM. Stem Cells 13:281.
43. Wang J, M Doedens, and J Dick. (1997). Primitive human hematopoietic cells are enriched in UC compared with adult BM or mobilized PB as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89:3919.
 44. Deutsch VR, TA Olson, A Nagler, et al. (1995). The response of UC megakaryocyte progenitors to IL-3, IL-6 and aplastic canine serum varies with gestational age. Br J Haematol 89:8.

Address reprint requests to:
Dr. Isaac Cohen
Northwestern University
345 East Superior Street, RIC 1407
Chicago, IL 60611

Ex Vivo Expansion of Early and Late Megakaryocyte Progenitors

PHIL LEFEBVRE,¹ JANE N. WINTER,² YURU MENG,¹ and ISAAC COHEN¹

ABSTRACT

Our goal is to produce *ex vivo*-expanded human megakaryocytes (MK) cells from peripheral blood progenitor cell (PBPC) harvests for use in supplementing conventional autografts. In this paper we show the megakaryocytopoietic productivity of small-scale *in vitro* serum-free cultures of human CD34⁺ cells containing MK growth and development factor (MGDF) and stem cell factor (*Kit* ligand; SCF) \pm granulocyte colony-stimulating factor (G-CSF). Cultures were characterized after 3, 6, 9, and 13 days by flow cytometry and clonogenic assays. CD34⁺ cells expanded 5.2- and 3.4-fold, and produced 2.2 and 2.4 CD34⁺/41⁺ cells per seeded CD34⁺ cell after 6 and 9 days in culture, respectively. None were detected at day 13. CD41⁺ cells expanded exponentially over 13 days. Colony-forming unit-megakaryocyte (CFU-MK) also expanded exponentially, but the proportion of the most primitive CFU-MK dropped from 45% to 1.5% and to <1% after 6 and 9 days, respectively. G-CSF increased total cell expansion, but decreased CD41⁺ frequency, yielding no gain in MK production. We also found that PB CD34⁺ cells cultured for 3–6 days are richer in primitive MK progenitors, while those cultured for 9–13 days have greater numbers of more differentiated MKs. Overall, the combination of MGDF+SCF proved sufficient for expanding CD34⁺/CD41⁺ cells. As the stage of *ex vivo* MK differentiation most conducive to optimal platelet production *in vivo* is not known, we are planning a clinical trial to determine the efficacy of *ex vivo*-expanded MKs on platelet recovery in relation to MK maturity.

INTRODUCTION

PATIENTS UNDERGOING HPC TRANSPLANTS to reconstitute hematopoiesis following myeloablative chemotherapy usually engraft neutrophils within 1–2 weeks, but often suffer from severe thrombocytopenia for as long as 2–3 weeks (1,2). Unfortunately, platelet transfusions are risky and costly (3), prompting a search for alternatives. Following the discovery of thrombopoietin (TPO) it was hypothesized that its administration, or analogs such as megakaryocyte growth and development factor (MGDF; [4,5]) to post-transplant thrombocytopenic patients might help to shorten the period of post-transplant thrombocytopenia (6). Unfortunately, preliminary results from phase I clinical trials using TPO or MGDF have shown

little or no effect on platelet recovery following myeloablative chemotherapy (7–11).

It has been shown that the rate of platelet recovery following stem cell transplantation correlates with the number of infused colony-forming unit-megakaryocyte (CFU-MK) and/or CD34⁺/41⁺ cells (12–14). These cells, which represent the megakaryocyte (MK) progenitor population, most likely promote platelet engraftment. While it is not always possible to obtain a sufficient number of MK progenitors for rapid platelet engraftment from mobilized PBPC collections alone, supplementation of conventional autografts with an *ex vivo*-expanded MK-rich product may enhance *in vivo* platelet production and shorten the period of thrombocytopenia. This approach was shown to be effective in a study in which *ex vivo*-

¹Department of Cell and Molecular Biology, and ²Division of Hematology/Oncology, Department of Medicine, and the Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, IL 60611.

³Preliminary results of this paper were presented as an abstract at the 1999 American Society of Hematology meeting.

expanded MK progenitors were administered to mice (15).

TPO alone has little proliferative effect on human CD34⁺ cells in culture. Studies have shown that the addition of early acting cytokines is required to increase total cell proliferation and MK expansion (16–18). This approach has been used in three phase I clinical trials in which the unprimed PBPC autograft was supplemented with an *ex vivo*-expanded MK-rich product, with variable effects on platelet recovery reported. In a clinical trial involving ten patients undergoing stem cell transplant who received cells expanded with MGDF, SCF, IL-3, IL-6, IL-11, Flt-3-ligand, and macrophage inflammatory protein-1 α , two out of the four patients receiving the highest numbers of infused MKs did not require platelet transfusions (19). In two other clinical trials using a combination of MGDF, SCF and G-CSF, the results were variable. One study reported sustained engraftment of neutrophils and platelets (20), while the other showed only an effect on neutrophil engraftment (21). In neither study were the expanded MKs characterized in terms of numbers of MK progenitors and/or differentiated MKs. This information would be valuable to correlate platelet response with the quality and quantity of MKs and MK progenitors. In this paper, we have characterized MK development at different durations of culture for the purpose of designing a clinical trial that will determine the ratio of expanded progenitors/differentiated MK most conducive to *in vivo* platelet engraftment.

MATERIALS AND METHODS

Preparation of low density nonadherent mononuclear cells from peripheral blood aphereses

All samples were collected after informed consent was obtained within the guidelines of the Northwestern University Institutional Review Board on Human Subjects. PBMC were collected by continuous flow apheresis from four breast cancer patients eligible for high-dose chemotherapy and autologous transplant and mobilized with G-CSF. Aliquots of PBMC were cryopreserved in fetal bovine serum (FBS) (GIBCO/Life Technologies, Gaithersburg, MD) with 10% DMSO and stored at -120°C until needed (up to 4 months). Ampules were thawed in a 37°C water bath and transferred to a thawing medium of α -thioglycerol-free Iscove's modified Dulbecco's medium (IMDM) (GIBCO) containing 20% FBS, 12.5 $\mu\text{g/ml}$ DNase I (Boehringer Mannheim, Indianapolis, IN), 12.5 U/ml preservative-free heparin (GIBCO), 100 μM Dulbecco's Modified Eagle's

nonessential amino acids (NEA, GIBCO), and 100 U/ml penicillin/100 $\mu\text{g/ml}$ streptomycin (PS, Boehringer Mannheim) at 4°C , kept on ice for 15–30 min, then centrifuged at $260 \times g$ for 10 min. Residual RBCs were lysed with Ortho-MuneTM lysing reagent (Ortho Diagnostic Systems, Raritan, NJ) and the remaining cells recovered by centrifugation for 6 min at $420 \times g$ through a 10% human serum albumin (HSA) (Baxter Hyland, Deerfield, IL) cushion. Adherent mononuclear cells were discarded following 2-h incubation at 37°C in a 5% CO_2 , fully humidified atmosphere, in IMDM containing 10% FBS supplemented with 100 μM NEA, 4 $\mu\text{g/ml}$ gentamicin, and PS.

Purification of CD34⁺ cells

CD34⁺ cells were purified using magnetic cell sorting (22) (MiniMACS System, Miltenyi Biotec, Auburn, CA) following the manufacturer's recommendations. Cells were passed over two columns and eluted with defined serum-free medium (Amgen, Thousand Oaks, CA). An average of $56.3 \pm 8.6\%$ of cells were viable as measured by the Trypan blue exclusion test and average purity was $60.7 \pm 12.5\%$ as assessed by flow cytometry.

Culture conditions

For each cytokine combination, 4×10^5 cells/ml were cultured in defined serum-free medium (Amgen), with MGDF and SCF (Amgen), with or without G-CSF (Amgen), all at 100 ng/ml. Cultures were maintained for 13 days at 37°C in a 5% CO_2 fully humidified atmosphere. Cultures were resuspended daily, and cells counted in the presence of Trypan blue. If cell concentration was $\geq 8 \times 10^5$, it was readjusted to 4×10^5 by diluting with fresh medium and cytokines. Clonogenic and flow cytometric analyses were performed at days 0, 3, 6, 9, and 13. Only the Trypan blue-negative cells were counted and used for calculating cell proliferation and MK production.

Flow cytometric analysis

Cell aliquots were washed in 1% BSA (Sigma) in PBS (GIBCO) with 5 mM EDTA (Sigma), designed to prevent further platelet activation and/or reverse adherence of activated platelets (13). After washing, the cells were stained for 15 min at 4°C in the dark with phycoerythrin-cyanin 5.1 (PC5) conjugated- α -CD34 (Clone 581, Coulter-Immunotech, Miami, FL) and either a combination of FITC- α -CD41 (Coulter-Immunotech) and PE-conjugated annexin V (R&D Systems, Minneapolis, MN) in the presence of 1% BSA-PBS + 2.5 mM CaCl_2 , or a combination of FITC- α -CD15 (Coulter-Immunotech) and PE- α -CD11 (Coulter-Immunotech), and analyzed by flow

cytometry. The negative controls were PC5-, PE- and FITC- α -mouse IgG₁ used at equivalent IgG₁ concentrations, and PE-Annexin V without calcium. Only the non-apoptotic high forward-scatter, low side-scatter (predominantly annexin V-negative) cell population was used for subset analysis (see Fig. 2A).

DNA degradation products (<2N DNA), reflecting apoptosis, and MK ploidy content were also measured by flow cytometry. CD41/annexin V-stained cells were washed again in 1% BSA-PBS and resuspended in 1 mg/ml sodium citrate with 50 μ g/ml 7-aminoactinomycin D (Sigma), then incubated for >30 min at 4–8°C in the dark (23). Samples were not fixed, but analyzed on the same day using three-color laser (Coulter Epics XL, Coulter Corp, Miami, FL).

Clonogenic assay

Clonogenic assays using a serum-free collagen medium containing TPO, IL-3 and IL-6 (MegaCult-C, Stem Cell Technologies, Vancouver, BC) for CFU-MK, and a serum-free methylcellulose medium containing SCF, GM-CSF, IL-3, IL-6 G-CSF, and EPO (MethoCult GF+, Stem Cell Technologies) for CFU-GM and BFU-E were performed according to the manufacturer's instructions. Briefly, viable cells from each day of assay were seeded at 10^3 /chamber. CFU-MK were scored after ten days by labelling with mouse anti-human CD41 followed by goat anti-mouse biotin-conjugated IgG. MK colonies were resolved by staining with avidin-conjugated alkaline phosphatase, reacting with substrate, and counter-staining with Evans blue. CFU-MK maturity was evaluated by counting the number of cells in each colony. Three size categories were distinguished: small mature colonies were those with ≤ 20 cells, medium-size colonies contained 21–50 cells, large immature colonies contained >50 cells. CFU-GM/BFU-E were scored after 14 days. BFU-E colonies were visually distinguishable by light-dense heme expression.

Statistical analysis

Paired comparisons were analyzed using the Wilcoxon signed rank nonparametric test. Statistical significance was given to any result with $p < 0.05$.

RESULTS

Total cell expansion

While there was no significant expansion of total cells at day 3, cell number increased exponentially thereafter (Fig. 1). The addition of G-CSF to MGDF+SCF signif-

icantly increased total viable cell proliferation three-fold at day 13, but had no significant effect at earlier time points. Despite the significant increase in total cell number, the frequency of nonviable cells did not significantly change during the culture period (Fig. 2A).

CD34⁺ and CD41⁺ cell expansion

Using MGDF+SCF, CD34⁺ cell frequency increased significantly during the first three days, but then decreased as cells differentiated, until CD34⁺ cells were not reliably detected at 13 days (Figs. 2B and 3A). Over time, the proportion of CD34⁺ cells that were also CD41⁺ increased (Fig. 3A). Due to overall cell proliferation the total number of CD34⁺ and CD34⁺/41⁺ cells per seeded CD34⁺ cell significantly expanded at 6 and 9 days compared with day 0 (Fig. 3B). No differences were seen when G-CSF was added to the cultures (data not shown).

As CD34⁺ cells matured and became committed to the MK lineage, total CD41⁺ cell production (CD34⁺/41⁺ plus CD34[−]/CD41⁺) increased exponentially, in parallel with total cell proliferation and the increase in CD41⁺ frequency (Figs. 3A and B). CD41⁺ cell frequency increased with MGDF+SCF with or without G-CSF at day 3, but there was no increase in CD41⁺ frequency after day 3 in the presence of G-CSF (data not shown). Overall, the increased total cell proliferation induced by G-CSF (Fig. 1) combined with the lower CD41⁺ frequency led to production of equal numbers of CD41⁺ cells, whether or not G-CSF was added (data not shown). In the presence of MGDF+SCF, mean frequency of




FIG. 1. Total cell expansion. The number of Trypan blue negative cells was counted at each time point, and divided by the number of seeded cells at day 0. □ MGDF+SCF; ■ MGDF+SCF+G-CSF. *Adding G-CSF significantly increased total cell expansion at day 13: $p < 0.05$.




FIG. 2. Changes in cell culture composition. Representative flow cytometry patterns showing the changes in cell viability and megakaryocyte development over 13 days of culture. (A) Cell viability: The population of cells demonstrating high forward scatter and low side scatter was considered the viable cell population. The percentage of viable cells is marked in each histogram. Viable cells were $>90\%$ annexin V-negative. Nonviable cells were predominantly annexin V-positive, indicating they had begun to apoptose. (B) Megakaryocyte development: The viable cell population in (A) was analyzed for CD34⁺ and CD41⁺ cell content (as well as CD15⁺ cell content, not shown). The percentage of CD34⁺/41⁻, CD34⁺/41⁺ and CD34⁻/41⁺ cells for each day is marked in the respective quadrants.

megakaryocytes with a ploidy greater than 4N reached $7.6 \pm 3.3\%$ at day 13, with most of these cells being only 8N. When G-CSF was added to MGDF+SCF, the mean frequency of megakaryocytes with a ploidy greater than 4N decreased insignificantly to $6.7 \pm 0.8\%$ at day 13.

Colony forming unit cell expansion

CFU-GM (Fig. 4A) and BFU-E frequencies (Fig. 4B) were proportionally similar to CD34⁺ frequency (Fig. 3A), also peaking at day 3, and declining thereafter. G-CSF treatment had no significant effect on any colony frequency (Fig. 4) or expansion (data not shown). CFU-MK frequencies were an order of magnitude less than but paralleled CD34⁺/41⁺ frequency, except at day 13, where CFU-MK, but not CD34⁺/41⁺ cells (Fig. 3A), could be reliably detected in all samples tested (Fig. 4C). Total CFU-MK (Fig. 5) increased rapidly in parallel with total cell proliferation and total CD41⁺ cells (Fig. 3B). However, there was a dramatic shift in the proportion of immature versus mature colonies. Total number of immature colonies, defined as CFU-MK with >50 cells per colony, expanded slightly at day 3, but then decreased rapidly by days 6 and 9. The proportion of immature CFU-MK in relation to the total CFU-MK population also decreased dramatically, from nearly 50% at day zero to undetected at day 13, in parallel with CD34⁺ cell frequency. Total numbers of intermediate-sized colonies (21–50 cells) peaked at day 6, then decreased, while their proportion changed in a manner similar to CD34⁺/

CD41⁺ cell frequency. The most mature colonies (≤ 20 cells/colony) paralleled total CD41⁺ cells. This correlates with the flow cytometric results, which showed that the vast majority of CD34⁺/41⁺ cells at day 9 were much dimmer in their CD34⁺ staining than at day 6, indicating a more mature, differentiated population (Fig. 2B, mean CD34⁺ PC5 fluorescence at day 6 = 8.83, peak = 10.2, Mean PC5 fluorescence at day 9 = 5.34, peak = 3.01).

DISCUSSION

Our goal is to produce a MK-rich product to be used as a supplement to conventional autografts to alleviate post-transplant thrombocytopenia. Our results show that the ratio of early MK progenitors versus differentiated megakaryocytes in the *ex vivo* expanded product changed dramatically over time. Cultures assayed at day 3 showed that, despite little total cell expansion, there was an increase in the number of early progenitors. As the culture progressed, early progenitor frequencies decreased, but their numbers expanded, driven by total cell expansion. Differentiated megakaryocytes emerged as the MK progenitors matured. Therefore, the maturation distribution of MK in a clinical *ex vivo* expansion protocol will be dependent upon the time of cell harvest.

We previously reported that cell seeding density can affect the expansion of MK progenitors (24). While seeding densities of 5×10^4 to 10^5 CD34⁺ cells/ml were used




FIG. 3. Target cell expansion. (A) CD34⁺/41⁻, CD34⁺/41⁺, and CD34⁻/41⁺ cell frequency. The frequency of CD34⁺, CD34⁺/41⁺, and CD41⁺ cells in the viable cell population using MGDF+SCF were measured by flow cytometry. □ CD34⁺/CD41⁻; ▨ CD34⁺/41⁺; ■ CD34⁻/41⁺. (B) CD34⁺/41⁻, CD34⁺/41⁺, and CD34⁻/41⁺ cell expansion. The total number of viable CD34⁺, CD34⁺/41⁺, and CD41⁺ cells found at each day were divided by the number of CD34⁺ cells seeded at day 0 to obtain total production per seeded CD34⁺ cell. □ CD34⁺/CD41⁻; ▨ CD34⁺/41⁺; ■ CD34⁻/41⁺. Notice change of scale in B.




FIG. 4. Colony-forming cell frequency. The percentage of 1000 seeded cells, obtained from liquid cultures after the indicated time, that developed into the various colonies assayed. A. CFU-GM frequency; B. BFU-E frequency; C. CFU-MK frequency. ■ Day 0, □ MGDF+SCF; ■ MGDF+SCF+G-CSF.




FIG. 5. Absolute CFU-MK numbers. The total number of colonies was calculated from CFU-MK frequency and total cell proliferation. Scale was changed at 150 to reflect the exponential growth of small colonies at day 6 and later. ■ Total colonies; ■ 3-20 cells/colony; ▨ 21-50 cells/colony; □ >50 cells/colony. Notice change of scale of Numbers of Colonies at 150.

in other clinical studies (19–21), we found that the higher seeding density used in this study (4×10^5 cells/ml) improved CFU-MK expansion (by 30% at day 3) and differentiated MK expansion (by 50% at day 13) compared with seeding at only 10^5 cells/ml (data not shown). By adjusting the cell concentration as expansion proceeds, we are able to obtain a greater cell number and MK yield without exhausting the culture medium and possibly harming the cells. Our results using PBMCs from cancer patients are comparable to results published using normal PBMC donors (25), indicating that the patients' underlying cancer has no effect on cell production. In addition, previous studies have shown that the process of CD34⁺ cell purification does not promote the expansion of any residual tumor cells that may be present in the PBMC harvest (26–29).

The optimal ratio of early MK progenitors versus differentiated megakaryocytes for rapid and sustained platelet engraftment is still not known. Previous studies have found a correlation between the number of infused MK progenitors and rapidity of platelet engraftment (12–14). A threshold number of approximately $1\text{--}3 \times 10^5$ MK progenitors/kg patient bodyweight (BW) seems to be required in an autograft for rapid platelet engraftment. Because not every patient can produce this number of MK progenitors, infusing additional *ex vivo*-expanded CD34⁺/CD41⁺ cells may improve platelet recovery.

While it is clear that greater numbers of CD34⁺/CD41⁺ cells infused can induce faster platelet engraftment, it can take over a week for even the most rapidly engrafting PB autograft patients to achieve platelet recovery. *In vivo*, MKs normally have a 16N modal ploidy, and must reach at least 8N ploidy to produce platelets (30,31). *In vitro*, over a week of culture is required for CD34⁺ cell-derived human MK to achieve ploidy greater than 4N and to begin to produce platelets (32,33). Because patients infused with even the highest numbers of MK progenitors cannot engraft any more rapidly than 1 week, this may indicate that early MK progenitors alone may not be sufficient to induce more rapid engraftment. It may be that a longer period (e.g., 9–13 days) of *in vitro* culture is required to allow megakaryocytes to mature enough to be able to produce platelets soon after infusion. However, infusion of large polyploid cells may increase the risk of blood vessel occlusion, leading to respiratory insufficiency.

Previous attempts to supplement conventional autografts with an *ex vivo*-expanded progenitor cell product produced mixed results as far as platelet engraftment is concerned (19–21). In the first study, Bertolini et al. (19) found that two of the four patients receiving $\geq 2.5 \times 10^5$ CD61⁺ cells/kg BW, *ex vivo*-expanded for 7 days, did not require platelet transfusions. In this study, MGDF, SCF, IL-3, IL-6, IL-11, Flt-3-ligand, and macrophage in-

flammatory protein-1 α were used to obtain optimal CFU-MK expansion. This is not practical in a clinical setting due to the difficulties associated with obtaining cytokines from multiple corporate sources. In two other studies using a combination of MGDF, stem cell factor, SCF and G-CSF to expand cells for 10 days, Reiffers et al. (20) showed accelerated platelet engraftment, with 11 of 14 patients requiring only one or no platelet transfusions, while McNiece et al. did not (21). Using only MGDF and G-CSF, we have obtained *in vitro* MK productivity equal to or better than that found by Bertolini et al. (19). We also confirmed that G-CSF did not improve MK production, but rather favored the myeloid lineage. Moreover, cultures without G-CSF had higher CD41⁺ frequency than those reported by the Reiffers group (34).

The positive results reported by Bertolini and Reiffers (19,20) clearly indicate that *ex vivo*-expanded MKs can help transplant patients avoid thrombocytopenic platelet nadirs. Possible explanations for this are that the infused cells were: (1) mature MKs, already capable of platelet production, or (2) low ploidy MK progenitors, which rapidly matured *in vivo*. Our results showed that even at day 13 only 7.6% of MKs had a DNA complement greater than 4N. This is in agreement with other reports showing poor *in vitro* MK nuclear maturation (16–32). Thus, it is unlikely that large ploidy MKs are responsible for the rapid platelet engraftment seen by the Bertolini and Reiffers groups (19,20). A more likely explanation is that the megakaryocytes were able to achieve rapid nuclear maturation once infused.

Our goal is to clarify whether early MK progenitors or more differentiated MKs are more beneficial for rapid platelet recovery. We are designing a clinical trial to assess the effectiveness of MKs harvested after different periods of culture and containing different proportions of progenitors and differentiated cells for accelerating platelet engraftment. While greater total cell expansion, containing large numbers of CFU-MK and MKs, were obtained at days 9 and 13, these cells are more mature and differentiated. On the other hand, at days 3 and 6 we found that there was significant expansion of CD34⁺ and CD34⁺/41⁺ as well as immature CFU-MK, with an increased number of primitive progenitors. We hope to show which product is most conducive to accelerating platelet recovery.

ACKNOWLEDGMENTS

The authors thank Dr. Graham Molineux of Amgen for supplying the cytokines used in this study. This work was supported by a grant from the U.S. Army Medical Research and Material Command (DAMD 17-98-I-8327), and in part by the Rehabilitation Institute of Chicago.

REFERENCES

1. Kessinger A, J Armitage, J Landmark, D Smith and D Weisenburger. (1988). Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following narrow ablative therapy. *Blood* 71:723-727.
2. Williams SF, JD Bitran, JM Richards, PJ DeChristopher, E Barker, J Conant, HM Golomb and AR Orlina. (1990). Peripheral blood-derived stem cell collections for use in autologous transplantation after high dose chemotherapy: An alternative approach. *Bone Marrow Transplant* 5: 129-133.
3. Webb IJ and KC Anderson. (1999). Risks, costs, and alternatives to platelet transfusions [review]. *Leukemia & Lymphoma* 34:71-84.
4. Bartley TD, J Bogenberger, P Hunt, YS Li, HS Lu, F Martin, MS Chang, B Samal, JL Nichol, S Swift, et al. (1994). Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. *Cell* 77:1117-1124.
5. Hokom MM, D Lacey, OB Kinstler, E Choi, S Kaufman, J Faust, C Rowan, E Dwyer, JL Nichol and T Grasel. (1995). Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. *Blood* 86:4486-4492.
6. Lok S and DC Foster. (1994). The structure, biology and potential therapeutic applications of recombinant thrombopoietin. *Stem Cells* 12:586-598.
7. Beveridge R, M Schuster, E Waller, R Stuart, C Abboud, S Cruickshank, D Menchaca, M Macri and D Connaghan. (1997). Randomized, double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor in breast cancer patients following autologous bone marrow transplantation. *Blood* 90:580a.
8. Bolwell B, J Vredenburgh, B Overmoyer, C Gilbert, L Chap, D Menchaca, D Scarlata and J Glaspy. (1997). Safety and biologic effect of pegylated recombinant human megakaryocyte growth and development factor in breast cancer patients following autologous peripheral blood progenitor cell transplantation. *Blood* 90:171a.
9. Glaspy J, J Vredenburgh, G Demetri, L Chap, C Gilbert, B Overmoyer, D Warren, R Berg, D Scarlata, D Menchaca and B Bolwell. (1997). Effects of pegylated recombinant human megakaryocyte growth and development factor before high-dose chemotherapy with peripheral blood progenitor cell support. *Blood* 90:580a.
10. Nash R, R Kurzrock, J DiPersio, S Nimer, J Vose, D Maharaj, C Linker, A Nademanee, R Negrin, M Ashby, T Tremblay, D Jones, F Appelbaum and R Champlin. (1997). Safety and activity of recombinant human thrombopoietin in patients with delayed platelet recovery. *Blood* 90:262a.
11. Linker C, P Anderlini, R Herzig, G Somlo, N Christiansen, J Fay, J Lynch, W Bensinger, T Goodnough, M Benyunes, M Ashby, D Jones and C Weaver. (1998). A randomized, placebo-controlled phase ii trial of recombinant human thrombopoietin (rhpo) in subjects undergoing high dose chemotherapy (hdc) and pbpc transplant. *Blood* 92:682a.
12. Takamatsu Y, M Harada, T Teshima, S Makino, S Inaba, K Akashi, T Shibuya and Y Niho. (1995). Relationship of infused CFU-GM and CFU-mk mobilized by chemotherapy with or without g-csf to platelet recovery after autologous blood stem cell transplantation. *Exp Hematol* 23: 8-13.
13. Dercksen MW, IS Weimar, DJ Richel, J Breton-Gorius, W Vainchenker, CM Slaper-Cortenbach, HM Pinedo, AE von dem Borne, WR Gerritsen and CE van der Schoot. (1995). The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent p-selectin-mediated binding of platelets. *Blood* 86:3771-3782.
14. Feng R, C Shimazaki, T Inaba, R Takahashi, H Hirai, T Kikuta, T Sumikuma, N Yamagata, E Ashihara, N Fujita and M Nakagawa. (1998). CD34(+)/CD41(+) cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 21: 1217-1222.
15. Ratajczak MZ, J Ratajczak, B Machalinski, R Mick and AM Gewirtz. (1998). In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia. *Blood* 91:353-359.
16. Debili N, F Wendling, A Katz, J Guichard, J Breton-Gorius, P Hunt and W Vainchenker. (1995). The mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. *Blood* 86:2516-2525.
17. Lefebvre P, JN Winter, AW Rademaker, C Goolsby and I Cohen. (1997). In vitro production of megakaryocytes from pixy321 versus GM-csf-mobilized peripheral blood progenitor cells. *Stem Cells* 15:112-118.
18. Williams JL, GG Pipia, NS Datta and MW Long. (1998). Thrombopoietin requires additional megakaryocyte-active cytokines for optimal ex vivo expansion of megakaryocyte precursor cells. *Blood* 91:4118-4126.
19. Bertolini F, M Battaglia, P Pedrazzoli, GA Da Prada, A Lanza, D Soligo, L Caneva, B Sarina, S Murphy, T Thomas and GR della Cuna. (1997). Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. *Blood* 89:2679-2688.
20. Reiffers J, C Cailliot, B Dazey, M Attal, J Caraux and JM Boiron. (1999). Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells [letter]. *Lancet* 354:1092-1093.
21. McNiece I, R Jones, SI Bearman, P Cagnoni, Y Nieto, W Franklin, J Ryder, A Steele, J Stoltz, P Russell, J McDermitt, C Hogan, J Murphy and EJ Shpall. (2000). Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. *Blood* 96:3001-3007.
22. Miltenyi S, W Muller, W Weichel and A Radbruch. (1990). High gradient magnetic cell separation with macs. *Cytometry* 11:231-238.
23. Jackson CW, LK Brown, BC Somerville, SA Lyles and AT Look. (1984). Two-color flow cytometric measurement of

MEGAKARYOCYTE EX VIVO EXPANSION

- DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions. *Blood* 63:768-778.
24. Lefebvre P, YR Meng, WM Miller, A Rademaker, T Papoutsakis, N Minster, CM Baum, JP McKearn, JN Winter and I Cohen. (1998). Increased megakaryocyte expansion with promegapoeitin-progenipoeitin combination and high seeding density. *Blood* 92:647a.
25. Koizumi K, K Sawada, M Yamaguchi, A Notoya, T Tarumi, H Takano, Y Fukada, M Nishio, E Katagiri, T Yasukouchi, N Sato, S Sekiguchi and T Koike. (1998). In vitro expansion of CD34+/CD41+ cells from human peripheral blood CD34+/CD41- cells: Role of cytokines for in vitro proliferation and differentiation of megakaryocytic progenitors. *Exp Hematol* 26:1140-1147.
26. Cancelas JA, S Querol, C Canals, J Bertran, A Limon, B Amill, J Petriz and J Garcia-Lopez. (1995). CD34+ cell positive selection from mobilized peripheral blood by an indirect immunomagnetic method: Effect of the type of mobilization and assessment of tumor depletion ability. *J Hematother* 4:531-538.
27. Colter M, M Jones and S Heimfeld. (1996). CD34+ progenitor cell selection: Clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. *J Hematother* 5:179-184.
28. Gazitt Y, CC Reading, R Hoffman, A Wickrema, DH Vesole, S Jagannath, J Condino, B Lee, B Barlogie and G Tricot. (1995). Purified CD34+ lin- thy+ stem cells do not contain clonal myeloma cells. *Blood* 86:381-389.
29. Tricot G, Y Gazitt, T Leemhuis, S Jagannath, KR Desikan, D Siegel, A Fassas, S Tindle, J Nelson, C Juttner, A Tsukamoto, J Hallagan, K Atkinson, C Reading, R Hoffman and B Barlogie. (1998). Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. *Blood* 91:4489-4495.
30. Ebbe S and FJ Stohlman. (1965). Megakaryocytopoiesis in the rat. *Blood* 26:20-34.
31. Levine RF, KC Hazzard and JD Lamberg. (1982). The significance of megakaryocyte size. *Blood* 60:1122-1131.
32. Guerriero R, U Testa, M Gabbianelli, G Mattia, E Montessoro, G Macioce, A Pace, B Ziegler, HJ Hassan and C Peschle. (1995). Unilineage megakaryocytic proliferation and differentiation of purified hematopoietic progenitors in serum-free liquid culture. *Blood* 86:3725-3736.
33. Choi ES, JL Nichol, MM Hokom, AC Homkohl and P Hunt. (1995). Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. *Blood* 85:402-413.
34. Lacombe F, JM Boiron, B Dazey, A Briaies, E Bascans, C Caillot, F Belloc and J Reiffers. (1999). Immunophenotype analysis of cytokine expanded CD34+ progenitor cells used for autologous transplantation. *Blood* 94:347b.

Address reprint requests to:

Dr. Issac Cohen

Northwestern University

345 East Superior Street, RIC 1407

Chicago, IL 60611

E-mail: i-c@northwestern.edu

Received August 10, 2000; accepted October 3, 2000

Murine prolactin-like protein E synergizes with human thrombopoietin to stimulate expansion of human megakaryocytes and their precursors

Phil Lefebvre^a, Jiandie Lin^b, Daniel I. H. Linzer^b, and Isaac Cohen^a

Departments of ^aMedicine and ^bBiochemistry,
Molecular Biology, and Cell Biology, Northwestern University, Chicago, Ill., USA

(Received 17 July 2000; revised 10 September 2000; accepted 18 September 2000)

Objective. The aim of this study was to determine the effect of promegakaryocytopoietic murine hormone prolactin-like protein E (PLP-E) on human megakaryocytopoiesis.

Materials and Methods. Human bone marrow CD34⁺ cells, cultured in serum-free medium with combinations of thrombopoietin (TPO), stem cell factor (SCF), Flt-3 ligand (Flt-3L), and PLP-E, were analyzed via microscopy, flow cytometry, and clonogenic assay.

Results. Unlike the situation with mouse cells, PLP-E alone did not promote human megakaryocyte (MK) differentiation, but instead synergizes with TPO to increase colony-forming unit megakaryocyte (CFU-MK), burst-forming unit erythroid (BFU-E), and colony-forming unit granulocyte erythroid macrophage mixed (CFU-GEMM) expansion, as well as total MK production. These effects can be attributed to an increase in colony frequency, combined with a significantly greater total cell expansion induced by adding PLP-E along with TPO. The number of cells in each CFU-MK colony is an indication of the maturity of the progenitor population, with larger colonies deriving from a more immature progenitor cell. PLP-E significantly expanded immature, intermediate, and mature CFU-MK subsets at 3 days of culture, as well as the intermediate and mature subsets at day 6. PLP-E combined with TPO induced significant expansion of all CFU-MK subsets at all time points. PLP-E further increased the effect of SCF and Flt-3L on TPO-induced total cell and CFU-MK expansion.

Conclusions. PLP-E may act as a survival factor for primitive human megakaryocytic and erythroid progenitors. It appears to preserve the highly proliferative immature fraction of the progenitor compartment but by itself does not promote total cell proliferation or human MK production. PLP-E may prove useful in combination with TPO and other cytokines for ex vivo expansion of hematopoietic progenitors to be used in a clinical setting. © 2001 International Society for Experimental Hematology. Published by Elsevier Science Inc.

Keywords: Prolactin-like protein—Megakaryocytopoiesis—hematopoietic progenitors

Introduction

Mammalian pregnancy—including that in mice and humans—is characterized by large increases in blood volume and in hematopoiesis. In rodents, megakaryocytopoiesis and platelet levels are elevated throughout gestation [1]. In human pregnancy, platelet production apparently increases to compensate for the dramatic increase in blood volume [2].

Thrombopoietin (TPO) is the primary regulator of megakaryocytopoiesis [3], but it is neither necessary nor sufficient for thrombopoiesis [4–6]. Increased platelet production during pregnancy is likely to result from the presence of higher concentrations of promegakaryocytopoietic cytokines. The

placenta is the major endocrine organ of pregnancy in terms of the amount and variety of hormones produced, providing cytokines responsible for the pregnancy-specific alterations in hematopoiesis. In mice, one such cytokine is the placental hormone prolactin-like protein E (PLP-E), a potent cytokine that stimulates murine megakaryocyte (MK) differentiation and the growth of other myeloid cell lineages [7–10]. PLP-E targets mouse MKs through a specific cell surface receptor and induces MK differentiation through a gp130-dependent signal transduction pathway [9].

In vitro, murine megakaryocytopoiesis from cultured hematopoietic cells progresses normally with just TPO treatment and achieves a 16N modal ploidy, similar to in vivo megakaryocytopoiesis [11–14]. Methodology to induce human MK to achieve a normal modal ploidy in vitro has not been described [4,6,15]. Such a goal is important, because

Offprint requests to: Isaac Cohen, Ph.D., Department of Medicine, Northwestern University Medical School, 345 East Superior Street, #1407, Chicago, IL 60611; E-mail: i-c@northwestern.edu

an agent that specifically enhances human MK production and maturation would be of great clinical use.

To offset posttransplant thrombocytopenia resulting from myeloablative therapy and stem cell rescue and to reduce or eliminate the need for platelet transfusions, methods have been developed for supplementing conventional stem cell transplants with an expanded MK-rich product [16–20]. Because TPO alone lacks the proliferative capacity to expand progenitors or MK in great numbers [21], this factor has been supplemented with pleiotropic early-acting cytokines [6,22]. However, these agents decrease MK frequency and maturation compared to using TPO alone [22,23]. Because cytokines often are functional across species (e.g., TPO), we investigated whether PLP-E might improve human MK yield and thus prove useful in developing methods to expand human MK *ex vivo* for transplantation.

Materials and methods

Preparation of low-density nonadherent mononuclear cells from peripheral blood aphereses

All samples were collected within the guidelines of the Northwestern University Institutional Review Board on Human Subjects.

Bone marrow, obtained from the femur of hematologically normal patients having total hip arthroplasty, was collected in anticoagulant designed to prevent platelet activation and containing final concentrations of 50 IU/mL preservative-free heparin (Life Technologies, Gaithersburg, MD, USA), 1 mM Na₂EDTA, and 0.1 mg/mL DNase I (Boehringer Mannheim, Indianapolis, IN, USA) in 20 mL of Iscove's modified Dulbecco's medium (IMDM; Life Technologies). Marrow cells were repeatedly extracted from bone fragments with IMDM containing 0.1 mg/mL DNase I (Boehringer Mannheim) and 4 µg/mL gentamicin (Life Technologies). The extract was homogenized by passage through a 21-gauge needle to remove bone fragments. Residual red cells were lysed with OrthoMune lysing reagent (Ortho Diagnostics, Raritan, NJ, USA) and the remaining cells recovered by centrifugation for 6 minutes at 420g through a 10% human serum albumin cushion.

Purification of CD34⁺ cells

CD34⁺ cells were purified using magnetic cell sorting (MiniMACS System, Miltenyi Biotec, Auburn, CA, USA) following the manufacturer's recommendations [24]. Cells were passed over two magnetic bead columns and eluted with X-Vivo 20 (BioWhittaker, Walkersville, MD, USA). There were 93.4% ± 1.0% cells determined to be viable using trypan blue (TB) exclusion test, and the average purity was 90.9% ± 1.7% as assessed by flow cytometry.




Figure 1. Binding of mouse PLP-E to human bone marrow cells. Purified CD34⁺ progenitors were cultured in the presence of SCF, TPO, and Flt-3L. Cells were spread onto glass slides and incubated with AP-PLP-E in the absence of competitor (A,B) or in the presence of GST-PLP-E (C) or GST (D), and stained for AP activity. Note the binding of AP-PLP-E to large differentiated MKs (>20% of cells) and smaller cells (B). Results are representative of three independent experiments. Bar = 100 µm.

•Preparation of fusion proteins

The PLP-E cDNA was linked in-frame to a secreted alkaline phosphatase (AP) gene in a mammalian expression vector described previously [9,25]. Fusion protein was obtained by transient transfection of the DNA construct into Chinese hamster ovary cells and subsequent collection of culture medium over a 2-day period. Medium containing secreted AP-PLP-E was concentrated and used in binding assays [9]. PLP-E without the AP fusion partner was generated by similar approaches and used as a competitor in binding experiments. The PLP-E cDNA also was fused to a glutathione S-transferase (GST) coding sequence to produce and purify GST-PLP-E fusion protein from bacteria; GST-PLP-E is biologically active [9].

Culture conditions

For each cytokine combination, 4×10^5 trypan blue-negative (TB^-) cells were seeded per milliliter of serum-free medium. Eleven different bone marrow samples were cultured. GST was used as a negative control in six cultures and was added to TPO in five cultures. Three cultures also had a set of samples treated with TPO, stem cell factor (SCF), and Flt-3 ligand (Flt-3L) with and without PLP-E. Cultures were maintained for 13 days at 37°C in a 5% CO_2 fully humidified atmosphere. TPO, SCF, and Flt-3L were obtained from R&D Systems (Minneapolis, MN, USA), and each was used at a concentration of 100 ng/mL. GST-PLP-E was used at a concentration of 4 μ g/mL. Cultures were counted at days 0, 3, 6, 9, and 13 in the presence of TB. If the number of cells per milliliter exceeded 8×10^5 , the culture was readjusted to 4×10^5 cells/mL by diluting with fresh medium and cytokines. Only TB^- cells were counted and used for calculating cell proliferation and MK production.

Hormone binding assay

Human hematopoietic cultures (described earlier) were obtained after 9 days in culture. Cells were placed onto glass slides and incubated with or without competitor for 30 minutes at room temperature before incubating with AP-PLP-E for 45 minutes. Binding conditions were as described previously [9]. Slides were washed briefly in Hank's balanced salt solution three times and fixed in a solution containing 20 mM HEPES (pH 7.4), 60% acetone, and 3% formaldehyde. After inactivating endogenous AP at 65°C for 30 minutes, the enzymatic activity derived from the fusion protein was detected by a chromogenic reaction.

Clonogenic assay

Clonogenic assays were performed on six cultures (three with GST controls) on days 0, 3, 6, and 9 according to the manufacturer's instructions. Analysis at day 13 was not done, as preliminary results showed that colony frequency was generally too low to be assayed accurately. Serum-free collagen medium containing TPO, interleukin-3 (IL-3), and interleukin-6 (IL-6; MegaCult-C, Stem Cell Technologies, Vancouver, BC, Canada) was used for colony-forming unit megakaryocyte (CFU-MK) and a serum-free methylcellulose culture medium containing erythropoietin, IL-3, IL-6, SCF, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor (MethoCult GF+, Stem Cell Technologies) was used for colony-forming unit granulocyte-macrophage (CFU-GM), colony-forming unit granulocyte erythroid macrophage mixed (CFU-GEMM), and burst-forming unit erythroid (BFU-E). One thousand cells from each sample at each time point were mixed with the assay medium and plated. CFU-MK colonies were scored after 10 days, and CFU-GM, CFU-GEMM,

and BFU-E after 14 days. CFU-MK maturity was evaluated by counting the number of cells in each colony. Three size categories were distinguished: small, mature colonies were those with ≤ 20 cells; medium-size colonies contained 21–50 cells; and large, immature colonies contained > 50 cells.

Flow cytometric analysis

Cell aliquots were washed in phosphate-buffered saline (PBS; Life Technologies) with 5 mM EDTA and 1% bovine serum albumin (BSA; Sigma Chemical Co., St. Louis, MO, USA) designed to prevent further platelet activation and/or reverse adherence of activated platelets [26]. After washing, the cells were stained for 15 minutes at 4°C in the dark with phycoerythrin-cyanin 5.1 (PC5)-conjugated- α -CD34 (Clone 581, Coulter-Immunotech, Miami, FL, USA), phycoerythrin (PE)-conjugated- α -CD41 (Coulter-Immunotech), and fluorescein isothiocyanate (FITC)- α -CD15 (Coulter-Immunotech) and analyzed by flow cytometry. Negative controls were PC5-, PE-, and FITC- α -mouse IgG₁ used at equivalent IgG₁ concentrations. Only the nonapoptotic high forward scatter, low side scatter cell population was used for subset analysis.

DNA degradation products ($< 2N$ DNA), reflecting apoptosis, and MK ploidy content were measured by flow cytometry. FITC- α -CD41-stained cells were washed again in 1% BSA-PBS and resuspended in 1 mg/mL sodium citrate with 50 μ g/mL 7-aminoactinomycin D (Sigma), then incubated for > 30 minutes at 4–8°C in the dark [27]. Samples were analyzed using three-color laser. All samples were analyzed on the same day.




Figure 2. Total viable cell expansion. Purified $CD34^+$ cells were cultured in serum-free medium in the presence of PLP-E (●), TPO (○), PLP-E + TPO (■), or GST control (*). Total TB^- cells were counted at each day and divided by the number of TB^- cells seeded at day 0 to determine the rate of cell expansion. *Significantly greater than TPO. N = 11; GST n = 6.

Statistical analysis

Total cell expansion was normalized per seeded viable (TB⁺) cell. All measured cell phenotypes were normalized per seeded CD34⁺ cell in each respective culture. A Wilcoxon signed rank nonparametric test was applied to each cytokine interaction or each parameter measured. A significant difference was determined for comparisons with $p < 0.05$.

Results

Binding of PLP-E to human hematopoietic cells

PLP-E was found to bind to cells derived from purified CD34⁺ cells cultured in the presence of TPO, SCF, and Flt-3L (Fig. 1A). PLP-E bound to large, differentiated cells morphologically similar to MK and to unidentified smaller

cells (Fig. 1B). The binding of AP-PLP-E was completely eliminated by addition of excess GST-PLP-E (Fig. 1C) but not control GST protein as competitor (Fig. 1D), indicating that the hormone is interacting with a specific and saturable cell surface receptor.

Effect of PLP-E on cell expansion

An effect of PLP-E on human hematopoiesis was assessed first in terms of the growth of primary bone marrow cells in culture. By day 6 in culture and continuing through day 13, the combination of PLP-E and TPO resulted in a synergistic increase in total cell expansion compared to either PLP-E or TPO alone (Fig. 2). Neither TPO nor PLP-E alone increased total cell expansion significantly more than the GST control samples. No difference was seen between TPO samples with or without GST (data not shown). PLP-E+TPO induced sig-




Figure 3. Progenitor cell production. CD34⁺ cell expansion (A) and production of CD34⁺CD41⁺ cells per seeded CD34⁺ cell (B) were obtained by multiplying the total TB⁺ cell expansion at each day by the frequency of CD34⁺ (C) or CD34⁺CD41⁺ (D) cells, respectively, and dividing by the number of CD34⁺ cells seeded at day 0. PLP-E (●), TPO (○), PLP-E+TPO (◐), or GST control (×). *Significantly greater than TPO.




Figure 4. Megakaryocyte production. Production of CD41⁺ cells per seeded CD34⁺ cell (A) was obtained by multiplying the frequency of CD41⁺ cells (B) cells in the TB⁺ cell fraction by the total cell expansion and dividing by the number of CD34⁺ cells seeded at day 0. PLP-E (●), TPO (○), PLP-E+TPO (◐), or GST control (✕). *Significantly greater than TPO.

nificantly greater CD34⁺ (Fig. 3A) and CD34⁺CD41⁺ (Fig. 3B) cell expansion by day 6 compared to TPO alone. This increase in progenitor expansion was primarily due to increased cell proliferation (Fig. 2), as the addition of PLP-E to TPO did not change the frequency of CD34⁺ or CD34⁺CD41⁺ cells in the total cell population compared to TPO alone (Fig. 3C–D).

Effect of PLP-E on MK production

The ability of PLP-E to induce growth of the MK cell population was investigated using CD41 (GPIIb) as a cell surface marker to identify MK cells. PLP-E combined with TPO produced significantly more CD41⁺ cells per seeded CD34⁺ cell by day 13 in culture than did TPO alone (Fig. 4A). PLP-E treatment did not alter the percentage of MK cells in the population (Fig. 4B), so again the effect of PLP-E appears to be due primarily to increased cell proliferation.

Colony formation

To determine if PLP-E also acts on progenitor cells to regulate colony-forming activity, cells were transferred to semi-solid medium after various days in liquid culture. Compared to controls or TPO alone, the combination of PLP-E and TPO significantly increased the expansion of CFU-MK, BFU-E, and CFU-GEMM at each day measured, but had no effect on CFU-GM expansion beyond the effect of TPO alone (Fig. 5A–D). PLP-E by itself significantly increased the number of CFU-GEMM obtained at 3 days in culture. TPO alone significantly increased CFU-MK frequency and expanded CFU-MK compared to day 0 and compared to control cultures treated with GST. In contrast to the liquid culture results, colony-forming assays also revealed that combining PLP-E and TPO further significantly increased the frequency of CFU-




Figure 5. Progenitor colony production. Cells were obtained from samples containing PLP-E (●), TPO (○), PLP-E+TPO (◐), or GST control (✕) at the time of seeding (day 0) or after 3, 6, or 9 days of culture and seeded into collagen-containing serum-free medium (CFU-MK) or methylcellulose (BFU-E, CFU-GM/GEMM). CFU-MK were scored 10 days after seeding, and CFU-GM/GEMM and BFU-E were scored 14 days after seeding. Analysis at day 13 was not done, as preliminary results showed that colony frequency was generally too low to be assayed accurately. Mean expansion was determined by multiplying colony frequency by total cell expansion at the day assayed for that sample. Frequency is the mean number of colonies per 100 total TB⁺ cells in culture. *Significantly greater than TPO. n = 6; GST n = 3.

MK, BFU-E, and CFU-GEMM, but decreased the frequency of CFU-GM compared to TPO alone (Fig. 5E–H).

CFU-MK maturation

Cells in the MK lineage range from primitive, highly proliferative cells to more mature cells that will soon leave the cell cycle and undergo terminal differentiation. To determine the stage at which PLP-E acts on the MK lineage, CFU-MK colony size was scored. Colonies arising from primitive cells will be larger, because these cells will proliferate extensively before differentiating; in contrast, colonies arising from mature




Figure 6. CFU-MK subfraction expansion. CFU-MK obtained in Figure 5 were scored based on colony size. Mean number of mature colonies (CFU-MK producing ≤ 20 cells), intermediate colonies (CFU-MK producing 21–50 cells), and immature colonies (CFU-MK producing > 50 cells) are plotted per 1,000 total cells from cultures containing PLP-E (●), TPO (○), PLP-E+TPO (◐), or GST control (✱) at each sample day. □ = subfractions at day 0. *Significantly greater than TPO. $n = 6$; GST $n = 3$.

cells will be small. The initial population of purified $CD34^+$ cells contained $2.4\% \pm 0.4\%$ CFU-MK. When colonies were assessed for relative maturity by size, $40.4\% \pm 5.6\%$ of the colonies were derived from primitive CFU-MK based on a colony size > 50 cells. Intermediate (21–50 cells/colony) and mature CFU-MK (< 20 cells) represented $28.9\% \pm 2.6\%$ and $30.7\% \pm 7.7\%$ of the seeded CFU-MK, respectively.

In cultures treated with PLP-E alone, all three CFU-MK subsets expanded at day 3, as well as the mature and intermediate subsets at day 6 compared to day 0 (Fig. 6). TPO-only treatment gave similar results, and TPO maintained an expanded number of mature and intermediate CFU-MK subsets at day 9. When cells were treated with PLP-E+TPO, all three subsets expanded significantly more than with TPO or PLP-E alone, and a significant total expansion of the primitive subset of CFU-MK was seen at days 6 and 9 compared to day 0. GST-treated control samples failed to produce any CFU-MK.

PLP-E performance in a progenitor cell expansion cocktail
TPO, SCF, and Flt-3L (long-term culture-initiating cell [LTC-IC] cocktail) are an optimal cytokine combination for




Figure 7. PLP-E increased cell proliferation induced by a progenitor cell cocktail. Purified $CD34^+$ cells were cultured in serum-free medium in the presence of PLP-E+TPO (●), TPO+SCF+Flt-3L (□), PLP-E+TPO+SCF+Flt-3L (■), or TPO control (○). Total TB^+ cells were counted at each day and divided by the number of TB^+ cells seeded at day 0 to determine the rate of cell expansion. $n = 3$.

the promotion of LTC-IC [28,29]. LTC-IC cocktail induced greater total cell expansion than PLP-E+TPO, and adding PLP-E to the LTC-IC cocktail had an additive effect on total cell proliferation (Fig. 7). SCF and Flt-3L also decreased $CD34^+CD41^+$ and $CD41^+$ frequency (Fig. 8), but PLP-E had no effect, similar to data shown in Figures 3D and 4B. However, PLP-E increased CFU-MK frequency when added to TPO, whereas SCF and Flt-3L decreased CFU-MK frequency (Fig. 9A). Thus, although SCF and Flt-3L did not increase the overall expansion of CFU-MK compared to TPO alone, PLP-E significantly increased it overall and synergized with SCF and Flt-3L to increase CFU-MK nearly four-fold compared to TPO at day 9 (Fig. 9B).

Discussion

We now have found that a recently described murine cytokine, PLP-E, contributes to the ex vivo expansion of the human MK and erythroid lineages through effects on CFU-MK, BFU-E, and their common precursor CFU-GEMM. The effect of PLP-E augments the action of other cytokines, such as TPO, SCF, and Flt-3L. PLP-E alone transiently in-




Figure 8. Decreased CD34⁺CD41⁺ and CD41⁺ frequency induced by a progenitor cell cocktail. Purified CD34⁺ cells were cultured in serum-free medium in the presence of PLP-E+TPO (●), TPO+SCF+Flt-3L (□), PLP-E+TPO+SCF+Flt-3L (■), or TPO control (○). Frequency of (A) CD34⁺CD41⁺ cells or (B) CD41⁺ cells in TB⁺ cells at each day as assayed by flow cytometry. *n* = 3.




Figure 9. CFU-MK production induced by LTC-IC cocktail. Cells were obtained from PLP-E+TPO (●), TPO+SCF+Flt-3L (□), PLP-E+TPO+SCF+Flt-3L (■), or TPO control (○) samples at the time of seeding (day 0) or after 3, 6, or 9 days of culture, seeded into serum-free collagen, and then scored 10 days after seeding. (A) Frequency is the mean number of colonies per 100 total cultured cells. (B) Mean expansion was determined by multiplying colony frequency by total cell expansion at the day assayed for that sample. *n* = 3.

creased the frequency and number of CFU-GEMM and immature CFU-MK in populations derived from purified CD34⁺ precursors. PLP-E in combination with TPO results in a synergistic expansion of total cells, primitive progenitors, and MK cells.

PLP-E induces murine MK differentiation through a gp130-dependent signal transduction pathway [9], and it is known that cytokines that signal via the gp130 receptor subunit may synergize with TPO to enhance megakaryocytopoiesis in both mice [14] and humans [30]. PLP-E, like TPO, appears to promote the survival of the most primitive MK progenitors, with TPO then acting to stimulate further growth and differentiation, especially of the MK lineage. In this way, PLP-E synergizes with TPO to expand MK. This interpretation is consistent with the greater number of large, immature CFU-MK in the presence of PLP-E and with the observed increase in total cell proliferation without a substantial decrease in CD34⁺CD41⁺ cell frequency when PLP-E and TPO are combined.

When scoring the effect of PLP-E by itself on the total CD34⁺ population in liquid culture, no response was seen in terms of proliferation, and no increase was detected in megakaryocytopoiesis. The inability of PLP-E by itself to promote human MK cell differentiation, whereas PLP-E stimulates increases in mouse MK cell size and ploidy [9], may result from differences in the systems used for human and mouse hematopoietic cell culture. It also is conceivable that human and mouse MK cell biology differ sufficiently to account for distinct responses to this hormone. Murine MK cells are capable of achieving a normal modal ploidy of 16N in culture [11,12,14], whereas human MK cells are not [4,6].

Although no PLP-E homologue is known in humans, the specific binding of PLP-E to human hematopoietic cells indicates that the unidentified PLP-E receptor may be functionally conserved between mouse and human species. Thus, humans may produce either a PLP-E that remains to be identified or a distinct ligand for the putative PLP-E receptor. It certainly is possible that PLP-E shares its receptor with other ligands, even within the mouse, because PLP-E is only detected in pregnant females, whereas the PLP-E receptor also is expressed in MK cells in nonpregnant female and male mice [9]. If the PLP-E receptor does bind multiple ligands, these ligands appear to be unknown. Binding studies using numerous other cytokines with megakaryocytopoietic activity have revealed no competition with PLP-E for receptor occupancy (data not shown).

PLP-E provides a means of enhancing the activity of currently available cytokine cocktails used to promote hematopoietic progenitor cell growth in culture. When compared to other early-acting cytokines such as SCF and Flt-3L in combination with TPO, PLP-E appears to target more specifically the MK compartment, resulting in a purer MK preparation. This effect may prove to be a significant advantage in ex vivo MK expansion for use in a clinical setting. That this mouse placental hormone also is capable of binding to human hematopoietic cells and stimulating their growth attests to the potential clinical value of identifying and characterizing new cytokine activities in model systems, especially when human homologues are not known (as is the case for PLP-E).

Acknowledgments

We thank Dr. Richard Wixson for supplying the bone marrows, and we thank Sigma Mostafa and Terry Papoutsakis for the human hematopoietic cell cultures used for protein binding assays. This work was supported by Grant R01 HD24518 from the National Institutes of Health to Dr. Linzer, by Grant DAMD17-98-1-8327 from the U.S. Army Breast Cancer Program to Dr. Cohen, and by the Rehabilitation Institute of Chicago to Dr. Cohen.

References

1. Jackson CW, Steward SA, Ashmun RA, McDonald TP (1992) Megakaryocytopoiesis and platelet production are stimulated during late pregnancy and early postpartum in the rat. *Blood* 79:1672
2. Davison JM, Lindheimer MD (1989) Volume homeostasis and osmoregulation in human pregnancy. *Baillieres Clin Endocrinol Metab* 3:451
3. Kaushansky K, Broudy VC, Lin N, et al. (1995) Thrombopoietin, the mpl ligand, is essential for full megakaryocyte development. *Proc Natl Acad Sci USA* 92:3234
4. Choi ES, Hukom MM, Chen JL, et al. (1996) The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. *Br J Haematol* 95:227
5. de Sauvage FJ, Carver-Moore K, Luoh SM, et al. (1996) Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. *J Exp Med* 183:651
6. Williams JL, Pipia GG, Datta NS, Long MW (1998) Thrombopoietin requires additional megakaryocyte-active cytokines for optimal ex vivo expansion of megakaryocyte precursor cells. *Blood* 91:4118
7. Lin J, Poole J, Linzer DIH (1997) Two novel members of the prolactin/growth hormone family are expressed in the mouse placenta. *Endocrinology* 138:5535
8. Muller H, Orwig KE, Soares MJ (1998) Identification of two new members of the mouse prolactin gene family. *Biochim Biophys Acta* 1396:251
9. Lin J, Linzer DIH (1999) Induction of megakaryocyte differentiation by a novel pregnancy-specific hormone. *J Biol Chem* 274:21485
10. Lin J, Toft DJ, Bengtson NW, Linzer DIH (2000) Placental prolactins and the physiology of pregnancy. *Recent Prog Horm Res* 55:37
11. Nakeff A, Dicke KA, van Noord MJ (1975) Megakaryocytes in agar cultures of mouse bone marrow. *Ser Haematol* 8:4
12. Wendling F, Maraskovsky E, Debili N, et al. (1994) C-mpl ligand is a humoral regulator of megakaryocytopoiesis. *Nature* 369:571
13. Broudy VC, Lin NL, Kaushansky K (1995) Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. *Blood* 85:1719
14. Zucker-Franklin D, Kaushansky K (1996) Effect of thrombopoietin on the development of megakaryocytes and platelets: an ultrastructural analysis. *Blood* 88:1632
15. Angchaisuksiri P, Carlson PL, Dessypris EN (1996) Effects of recombinant human thrombopoietin on megakaryocyte colony formation and megakaryocyte ploidy by human CD34+ cells in a serum-free system. *Br J Haematol* 93:13
16. Bertolini F, Battaglia M, Pedrazzoli P, et al. (1997) Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. *Blood* 89:2679
17. Ratajczak MZ, Ratajczak J, Machalinski B, Mick R, Gewirtz AM (1998) In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia. *Blood* 91:353
18. Andrews RG, Briddell RA, Hill R, Gough M, McNiece IK (1999) Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia. *Stem Cells* 17:210
19. McNiece I, Jones R, Cagnoni P, et al. (2000) Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. *Blood* 96:3001
20. Reiffers J, Cailliot C, Dazey B, Attal M, Caraux J, Boiron JM (1999) Abrogation of post-myeloablative chemotherapy neutropenia by ex vivo expanded autologous CD34-positive cells. *Lancet* 354:1092
21. Sitnicka E, Lin N, Priestley GV, et al. (1996) The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. *Blood* 87:4998
22. Gehling UM, Ryder JW, Hogan CJ, et al. (1997) Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. *Exp Hematol* 25:1125
23. Dolzhanskiy A, Basch RS, Karpatsky S (1997) The development of human megakaryocytes: III. Development of mature megakaryocytes from highly purified committed progenitors in synthetic culture media and inhibition of thrombopoietin-induced polyploidization by interleukin-3. *Blood* 89:426
24. Miltenyi S, Muller W, Weichel W, Radbruch A (1990) High gradient magnetic cell separation with MACS. *Cytometry* 11:231
25. Muller H, Dai G, Soares MJ (1998) Placental lactogen-I (PL-I) target tissues identified with an alkaline phosphatase-PL-I fusion protein. *J Histochem Cytochem* 46:737
26. Dercksen MW, Weimar IS, Richel DJ, et al. (1995) The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent p-selectin-mediated binding of platelets. *Blood* 86:3771
27. Jackson CW, Brown LK, Somerville BC, Lyles SA, Look AT (1984) Two-color flow cytometric measurement of DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions. *Blood* 63:768
28. Luens KM, Travis MA, Chen BP, Hill BL, Scollay R, Murray LJ (1998) Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+thy-1+lin- cells with preserved ability to engraft SCID-hu bone. *Blood* 91:1206
29. Ramsfjell V, Bryder D, Bjorgvinsdottir H, et al. (1999) Distinct requirements for optimal growth and in vitro expansion of human CD34+CD38- bone marrow long-term culture-initiating cells (LTC-IC), extended LTC-IC, and murine in vivo long-term reconstituting stem cells. *Blood* 94:4093
30. Sui X, Tsuji K, Ebihara Y, et al. (1999) Soluble interleukin-6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34+ cells through glycoprotein (gp)130 signaling. *Blood* 93:2525

Fibronectin- and protein kinase C-mediated activation of ERK/MAPK are essential for proplateletlike formation

Fang Jiang, Yuzhi Jia, and Isaac Cohen

The megakaryoblastic CHRF-288 cell line was used to investigate signal transduction pathways responsible for proplateletlike formation (PPF). The role of fibronectin (FN) and protein kinase C (PKC) activation in PPF were examined. In the presence of serum and phorbol 12-myristate 13-acetate (PMA), a PKC activator, cells exhibited full megakaryocytic differentiation, manifested by adhesion, shape change, increased cell size, polyploidy, PPF, and expression of CD41⁺, CD61⁺, and CD62P⁺. The same morphologic and phenotypic features were observed in serum-free cultures in the presence of FN/

PMA. Only partial differentiation occurred when other integrin ligands were substituted for FN. FN alone induced minimal cell adhesion and spreading, while PMA alone induced only polyploidy without adhesion. Signal transduction changes involved the activation of the extracellular signal-regulated protein kinase 1 (ERK1)/ERK2 as well as c-Jun amino-terminal kinase 1 (JNK1)/stress-activated protein kinase (SAPK). Phosphoinositide-3 kinase and p38 were not stimulated under these conditions. Inhibitors were used to identify the causal relationship between signaling pathways and PPF.

PD98059 and GF109203X, inhibitors of ERK1/ERK2 pathway and PKC, respectively, blocked PPF, while adhesion, spreading, and polyploidy were normal. These studies show that activation of ERK1/ERK2 mitogen-activated protein kinase pathway plays a critical role in PPF. The elucidation of the signal transduction pathway on megakaryocyte development and PPF is of crucial importance for understanding this unique biological process. (Blood. 2002;99:3579-3584)

© 2002 by The American Society of Hematology

Introduction

Megakaryocytopoiesis involves proliferation of megakaryocyte (MK) progenitors and differentiation. Following a few mitotic cycles, an aborted mitotic process takes place in which prophase, metaphase, and initial anaphase stages are normal while late anaphase and telophase are deficient.^{1,2} Cytokinesis does not take place, and endoreplication cycles lead to polyploidy.³ Nuclear maturation proceeds in concert with cytoplasmic differentiation and expression of megakaryocytic markers. Cytoplasmic maturation occurs at different ploidy levels and results in platelet production (thrombopoiesis). There are different hypotheses pertaining to platelet formation and release from mature MKs. In one model, the demarcation membrane system outlines nascent platelets derived from the interior of the cytoplasm.^{4,5} Tubular-branching demarcation membranes may be reorganized by a process of fusion-fission into flat sheets of membrane with subsequent shedding of platelets into the circulation.⁶ In another model, platelets are thought to be released from extruded long cytoplasmic extensions by rupture of the slender links between them.⁷⁻⁹ Proplateletlike formation (PPF) *in vitro* follows cell adhesion and polyploidization.^{10,11}

Protein kinase C (PKC) is a family of serine/threonine protein kinases in the cytosol involved in pleiotropic processes such as cell growth, differentiation, and cytokine secretion.^{12,13} The role of PKC signaling in MK differentiation has been well established over the past 2 decades. In several cell lines, PKC activation by the agonist phorbol 12-myristate 13-acetate (PMA) induced MK

differentiation, including cell cycle arrest, secretion of cytokines, up-regulation of MK surface antigens, polyploidization, development of proplatelet processes, and appearance of demarcation membranes.¹⁴⁻¹⁶ Integrins, which are heterodimeric transmembrane protein receptors, mediate cell membrane-extracellular matrix interaction and have profound effects on cell division, differentiation, and survival.¹⁷ It has become clear that integrins not only mediate the physical attachment of cells to extracellular matrix but also generate a variety of signals to the interior of the cell¹⁸⁻²⁰ and regulate cell growth, survival, and gene expression.²¹⁻²⁴ Integrin-mediated cell adhesion has been shown to strongly activate mitogen-activated protein kinase (MAPK), a key downstream effector of the Raf signaling pathway in Swiss 3T3/REF52 fibroblasts²⁵ and NIH3T3 fibroblasts.²⁶⁻²⁷ PKC activation and integrin engagement signaling pathways play different roles in physiological processes and may generate cross-talk resulting in either up-regulation or down-regulation, according to the particular demands of different cells.

MAPKs are serine/threonine kinases that are highly conserved in eukaryotic cells from yeast to human. Several signaling cascades classified as MAPK pathways include extracellular signal-related kinase kinase (MEK)-extracellular signal-regulated protein kinase 1 (ERK1)/ERK2; MEK-c-Jun amino-terminal kinase (JNK)/stress-activated protein kinase (SAPK); and MEK-p38. These pathways have been identified as mediating cell proliferation, survival, differentiation, and apoptosis. While the ERK pathway responds

From the Department of Cell and Molecular Biology and the Department of Pathology, Northwestern University, Chicago, IL.

Submitted October 9, 2001; accepted January 14, 2002.

Supported in part by grant DAMD17-98-1-8327 from the US Army Breast Cancer Program and a grant from the Rehabilitation Institute of Chicago, both awarded to I.C.

Reprints: Fang Jiang, Northwestern University, 345 E Superior St, RIC Rm 1407, Chicago, IL 60611; e-mail: f-jiang2@northwestern.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2002 by The American Society of Hematology

mainly to mitogens and growth factors and regulates mammalian cell proliferation and differentiation, the JNK/SAPK MAPK pathway is associated with stress and apoptosis.²⁸ The p38 MAPK pathway is activated in response to cellular stress and inflammation and is involved in many fundamental biological processes.²⁹⁻³¹

Phosphoinositide-3 kinase (PI3K) is known to initiate several signaling pathways,³² and recently, it has also been found to stimulate the activation of the ERK1/ERK2 MAPK cascade in some signaling systems as well. Cross-talk and signal integration mechanisms among all these pathways have been described.

While primary MKs have been separated by different methods,³³⁻³⁶ the yield and degree of purity of the cells are relatively poor, and consistent PPF is lacking. The study of human megakaryocytopoiesis and thrombopoiesis requires the development of either long-term culture systems derived from normal MKs or permanent cell lines derived from transformed MKs. Therefore, for the purpose of clarifying the mechanism/signal transduction of PPF, we chose a human megakaryoblastic CHRF-288 cell line as a culture model that has proved to be valuable for the study of MKs and MK-associated functions.³⁷ Our results showed that PPF in CHRF-288 cells needed 2 critical steps: fibronectin (FN) binding to the cell and activation of intracellular PKC by PMA. The activation of the MEK/ERK pathway induced by FN binding and the activation of PKC are necessary for PPF. Our results suggest substantial overlaps and cross-talk between the integrin engagement pathway, PKC activation, and the Ras/MEK/MAPK cascade.

Materials and methods

Materials

The human CHRF-288 megakaryoblastic cell line was generously provided by Dr Fern Tablin (Davis, CA) and Dr Michael Lieberman (Cincinnati, OH). PMA, extracellular matrix proteins, and BCIP (5-bromo-4-chloro-3-indolylphosphate)/nitroblue tetrazolium (NBT) liquid substrate system were from Sigma (St Louis, MO). Thrombopoietin (TPO) was from R&D (Minneapolis, MN). Proteinase inhibitors were from Boehringer Mannheim (Germany). Tris-glycine gel was from Gradipore (Frenchs Forest, New South Wales, Australia). Nitrocellulose membrane was from Amersham (Les Ulis, France). ERK1/ERK2 MAPK antibody, phosphorylated ERK1/ERK2 MAPK antibody, and goat antirabbit immunoglobulin G (IgG) alkaline phosphatase conjugate were from Promega (Madison, WI). The p38 MAPK antibody and phosphorylated p38 MAPK antibody, the JNK/SAPK antibody and phosphorylated JNK/SAPK antibody, and the PI3K/Akt antibody and phosphorylated PI3K/Akt (Ser and Thr) antibodies were from New England Biolabs (Beverly, MA). Signaling pathway inhibitors PD98059, SB203580, Wortmannin, LY294002, and GF109203X were from Calbiochem (San Diego, CA).

Cell culture

CHRF-288 cells were cultured in Fischers medium (Sigma) supplemented with 20% fetal bovine serum (FBS) (Gibco, Gaithersburg, MD), as a source of growth factors and integrin ligands, and 4 mg/L gentamicin. To identify the serum factor(s) responsible for MK differentiation, serum-free culture was carried out with X-vivo 20 culture medium (Biowhitaker, Walkersville, MD)³⁸ in plates coated with extracellular matrix proteins, such as FN, vitronectin (VN), laminin (LN), collagen I (CI), and collagen IV (CIV). Poly-D-lysine and bovine serum albumin (BSA) were used as controls. The coating procedure involved dissolving the matrix protein in phosphate-buffered saline (PBS) at a concentration of 50 µg/mL and using it in 12-well culture plates (200 µL per well). Plates were left at 4°C overnight, washed with PBS, and incubated with a blocking agent (1% BSA) for 2 hours at 37°C before the onset of culture. PMA (10 ng/mL) was used to promote cell differentiation. The model culture system for PPF included X-vivo 20 plus

FN plus PMA. When inhibitors of signaling pathways were used, they were added to the culture 1 hour prior to PMA addition.

Morphologic assay

Differentiated cells were counted by means of micrometer grids in 1-mm² areas. Under the 10 × objective lens, the left edge of each culture well was used as the first field; the adjacent 5 fields were counted one by one. Adherent and differentiated cells were stained *in situ* with Wright Giemsa stain for 15 to 30 minutes, or photographed directly with an LSM510 laser microscope (Zeiss, Jenna, Germany).

Electron microscopy

Cells or plateletlike particles were fixed in 2% glutaraldehyde, washed with cacodylate buffer, postfixed with 1% osmium tetroxide and uranyl acetate, dehydrated in graded alcohol and propylene oxide, and then embedded with Epon. Ultrathin, 60-nm sections were cut, stained with uranyl acetate and lead citrate to enhance contrast, and examined in a JEOL-100CX electron microscope (Tokyo, Japan).

Flow cytometry for phenotypic analysis

Cells were counted and viability was assessed by the trypan blue exclusion method. For flow cytometry, cells were washed in PBS containing 1% BSA and then stained for 15 minutes on ice in the dark with fluorescent dye-conjugated monoclonal antibodies specific for MK markers (CD41, CD61, and CD62P) or early myeloid cell markers (CD33 and CD90) (Beckman Coulter, Brea, CA). Corresponding negative controls were fluorescein isothiocyanate-antimouse IgG, phycoerythrin-antimouse IgG, and Cy5-antimouse IgG (Beckman Coulter) used at equivalent IgG concentrations. Each sample contained 5 × 10⁵ cells. Flow cytometric analysis was performed by means of a Coulter Cytometry XL dual laser flow cytometer (Coulter, Hialeah, FL).

Ploidy analysis

Nonadherent cells were collected by centrifugation. Adherent cells were first dislodged with 0.05% trypsin in 0.33 mM EDTA, and the viable cells counted by trypan blue exclusion. Then, 5 × 10⁵ cells per sample were washed in PBS containing 1% BSA. DNA was stained with 7-amino-actinomycin D (7-AAD) (Calbiochem) following a one-step fixation-permeabilization with the ORTHO PermeaFix reagent (J & J, Raritan, NJ). The ploidy classes were then determined following flow cytometric analysis.

Protein extraction and Western blot analysis

Cells were collected at 5 minutes, 30 minutes, 1 hour, 2 hours, 24 hours, 48 hours, and 72 hours after PMA treatment in different culture conditions. Nonadherent and dislodged adherent cells were centrifuged at 400g for 5 minutes, and the cell pellets lysed in a buffer containing 30 mM Hepes, 100 mM NaCl, 10 mM benzimidazole, 1 mM EDTA, 1% Triton-X-100, and 20 mM NaF, adjusted to pH 7.5. The following protein and phosphatase inhibitors were then added: 1 mM phenylmethyl sulfonyl fluoride, 10 µg/mL aprotinin, 5 µg/mL leupeptin, 2 µg/mL pepstatin, 1 mM Na₃VO₄. Cell lysates were cleared by centrifugation at 16 000 rpm for 5 minutes at 4°C. The protein concentrations were measured by means of protein/DC Assay (Bio-Rad, Hercules, CA) to ensure equal electrophoretic loading. Lysates were denatured by boiling for 5 minutes in Laemmli sample buffer and loaded at a concentration of 20 µg protein per lane on 10% Tris-glycine iGel. Proteins were then transferred to nitrocellulose membranes and blocked for 16 hours in Tris-buffered saline containing 0.05% Tween 20 and 1% BSA. To ensure equal protein loading, duplicate gels were stained by Ponceau S (Sigma). Antibodies against signal proteins or phosphorylated signal proteins were used to determine the activation of the kinases during cell differentiation. Each antibody was diluted in blocking buffer at the concentration recommended by the supplier and incubated with the blot at room temperature for 2 hours or at 4°C overnight, then incubated with alkaline phosphatase conjugate for 1 hour at room temperature, and color-detected by BCIP/NBT substrate liquid system.




Figure 1. Cell morphology in serum-containing culture medium. Cells were cultured for 3 days. (A) Undifferentiated cells cultured in 20% FBS-containing medium. Original magnification $\times 200$. (B) PMA-induced full differentiation in serum-containing medium, showing adherence, size increase, polyploidization, and proplatelet formation. In situ Giemsa staining. Original magnification $\times 200$. (C) Electron micrograph showing a differentiated cell with an elongated cytoplasmic process. Original magnification $\times 3000$. (D) Ploidy of undifferentiated cells. (E) Ploidy of differentiated cells. Nonadherent cells and adherent cells (dislodged by means of 0.05% trypsin-EDTA) were collected by centrifugation. Cells were stained with 7-AAD as indicated in "Materials and methods" and analyzed by flow cytometry. Representative of 5 independent experiments.

Statistical analysis

Statistical analysis was performed by means of the 2-tailed Student *t* test for unpaired data in phenotypic, ploidy, and morphologic analysis.

Results

CHRF-288 cell differentiation in serum-containing medium

In the absence of PMA stimulation in serum-containing culture medium, CHRF-288 cells were nonadhesive and proliferated actively (Figure 1A). However, after 5 minutes of exposure to PMA (10 ng/mL), they gradually underwent full differentiation, including adhesion, spreading, size increase, polyploidization, and PPF (Figure 1B), reaching maximal differentiation after 3 days. Thereafter, cells detached from the substrate and underwent apoptosis and cell death. The cells with PPF were characterized by electron microscopy. These elongated cytoplasmic processes (Figure 1C) contained cytoskeletal structures, mitochondria, rough endoplasmic reticulum, macrovesicles, and α -granule-like organelles, but no microtubules were observed. Similar morphology was observed for the plateletlike particles, and no marginal microtubular rings, typical of platelets, were seen. The particles did not aggregate with adenosine 5'-diphosphate or thrombin. The timing of the differentiation stages was dependent on PMA concentration (1 ng/mL, 10 ng/mL, or 100 ng/mL). The higher the PMA concentration, the more rapid the differentiation pattern. Without PMA addition, cells showed few adhesion and shape change patterns (Figure 1A). TPO had no effect on the differentiation of CHRF cells.

PMA treatment altered the cell surface expression of some membrane proteins (Table 1). CD33⁺, CD90⁺, and CD62P⁺ cells significantly decreased, while CD41⁺ and CD61⁺ did not change. Although cultured CHRF cells show a 2N-4N ploidy pattern in the absence of PMA (Figure 1D), the addition of PMA led to a significant increase of the DNA content and ploidy distribution, with the appearance of 4N to 64N polyploid cells (Figure 1E).

FN is the integrin ligand responsible for full differentiation

Different integrin ligands were substituted for serum in the culture medium. While FN alone induced minimal adhesion and shape change, PMA alone induced increased size and polyploidy in the absence of adhesion; FN and PMA costimulation induced full cell differentiation/PPF (Figure 2A). In this culture system, the morphologic features of PPF and functional tests of the particles were similar to the data obtained in serum-containing culture. PMA-treated cells cultured in the presence of LN increased in size without adhesion or PPF. PMA-treated cells cultured in the presence of VN-, CI- and CIV-coated wells showed minimal adhesion and PPF (Figure 2B). No adhesion or differentiation occurred with either BSA or poly-D-lysine-coated culture wells. We determined that the optimal culture model for differentiation and PPF involves seeding CHRF cells at a concentration of 2.5 to 5×10^4 cells per milliliter in X-vivo 20 in the presence of PMA (10 ng/mL) in FN-coated dishes for 3 to 4 days. Using this culture model in a well-defined medium resulted in more consistent PPF than the use of serum in the culture medium.

Activation of ERK1/ERK2 is essential for full differentiation and PPF

The differentiation of CHRF cells can be viewed as the result of a balance between stimulatory and inhibitory signals. Western blots were used to identify the activation of signaling molecules related to PPF. When cells were treated with FN alone, a faint phosphorylation signal of ERK1/ERK2 was detected after 1 day of culture (Figure 3A, upper panels). With PMA alone, on the other hand, a weak and quick phosphorylation signal of ERK1/ERK2 was detected within 5 minutes and diminished with time (Figure 3A, middle panel). With both FN and PMA present in the culture, a strong phosphorylation of ERK1/ERK2 occurred. The activation of ERK1/ERK2 was rapid, occurring within 5 minutes of exposure to PMA. The maximum expression of phosphorylated ERK1/ERK2 occurred 30 minutes after PMA treatment, when the cells had firmly adhered to the FN substrate. PMA rapidly and persistently induced the phosphorylation of ERK1/ERK2, but the expression of the kinase tapered with time (Figure 3A, lower panel). Use of the inhibitors PD and GFX in the culture system blocked phosphorylation of ERK1/ERK2, as did a high dose of SB (50 μ M) (Figure 3B).

Table 1. Immunocytochemical characteristics

Antigen cluster designation, % reactivity	Undifferentiated cells, %	Differentiated cells, %	P value
CD33	99.5	81.3	< .01
CD41	72.5	81.2	.39
CD61	54.4	63.9	.33
CD62P	49.6	25.3	.01
CD90	93.4	61.8	< .01

Data are from a flow cytometric analysis of cultured CHRF-288 cells. Cells stained with specific surface antibody conjugated with fluorescent dye as indicated in "Materials and methods." The percentages are percentages of the total number of cells. Five independent experiments were performed.




Figure 2. Effect of single matrix protein on CHRF cell morphology with or without PMA treatment in serum-free medium culture. (A) Cells cultured in serum-free medium with different combinations. Full cell differentiation, including PPF, occurred only in FN/PMA costimulation. Original magnification $\times 200$. (B) Culture dishes were coated with a single matrix protein (50 $\mu\text{g}/\text{mL}$) overnight. Cells were cultured in serum-free medium in the presence of PMA (10 ng/mL) and a single matrix protein for 3 days. Cells were seeded at a concentration of 2.5×10^4 cells per milliliter and counted in 1-mm² areas by means of phase contrast microscopy. SM, serum-containing medium; SFM, serum-free medium. Graph depicts the means \pm SE from at least 5 experiments.

To determine a causal relationship between signaling and PPF, we supplemented our culture model system with various signaling inhibitors to identify the pathway responsible for differentiation of the CHRF-288 cells (Figure 4). The inhibitors were added to cells 1 hour before PMA addition. PD98059 (10 μM and 50 μM) and GF109203X (5 μM), inhibitors of upstream of ERK1/ERK2-MAPK and PKC,³⁹ respectively, blocked PPF but not adhesion or size increase. While a low dose of SB203580 (10 μM), an inhibitor of p38 MAPK⁴⁰ and JNK/SAPK⁴¹ pathways, did not affect cell differentiation, a high dose (50 μM) of SB blocked the differentiation. Wortmannin (100 nM and 500 nM), an inhibitor of PI3K/Akt pathway,³⁹ did not affect cell differentiation. A high dose of GF109203X (25 μM) was cytotoxic for cells as determined by the trypan blue exclusion test, and the cell body shrank.

Activation of JNK1/SAPK but not p38 and PI3K

Costimulation of cells with FN/PMA induced phosphorylation of JNK1(46 kd)/SAPK within 5 minutes of PMA addition, and this activation lasted at least 2 hours (Figure 5A). Low and high doses of SB (10 and 50 μM) blocked phosphorylation of JNK1 (Figure 5B), but only a high dose of SB blocked PPF (Figure 4C). JNK1/SAPK is therefore not involved in PPF. Neither p38 MAPK

nor PI3K/Akt (Ser473 and Thr308) were activated following FN/PMA stimulation (data not shown).

Discussion

The identification of the signaling pathway responsible for megakaryocytic differentiation, PPF, and platelet release is still debated. In this study, we sought to characterize the MAPK-specific targets in CHRF-288 cells stimulated by FN/PMA. Rapid and prolonged activation of ERK1/ERK2 MAPK was found necessary for PPF.

We first investigated a series of integrin ligands for their effects on PPF.¹⁷ As a main component of matrix protein, FN binds to several megakaryocyte integrins, such as $\alpha\text{IIb}\beta_3$, $\alpha\text{v}\beta_3$, $\alpha\text{v}\beta_5$, and $\alpha 5\beta_1$. In this study, when CHRF cells were cultured in serum-free medium in FN-coated dishes, only later-term and weak phosphorylation of ERK1/ERK2 and minimal adhesion were observed. With the addition of PMA, a PKC activator used at a moderate concentration that did not down-regulate PKC,⁴² the cells showed a dramatic full differentiation pattern that included PPF, and concomitant activation of ERK1/ERK2. The binding to other matrix proteins, VN, CI, and CIV, with PMA treatment resulted in minimal cell adhesion and occasional PPF.

PKC activation with PMA is known to induce a series of biological processes related to differentiation correlating with the activation of MAPK.⁴³ In our study, activation of PKC by PMA in the absence of FN resulted in weak and rapid phosphorylation of ERK1/ERK2; however, cells increased only in size and ploidy, without either adhesion or PPF. While the polyploidy pattern is similar in the presence of PMA alone and of PMA/FN, only the




Figure 3. Correlation of ERK1/ERK2 MAPK activation with PPF. Cells were cultured in FN/PMA for 3 days and analyzed by Western blot. (A) Time course of ERK1/ERK2 phosphorylation in the cultures with the FN/PMA combination or with FN or PMA alone. The upper panels show that phosphorylation of ERK1/ERK2 was faintly expressed in the presence of FN alone after 1 day of culture. The middle panel shows that phosphorylation of ERK1/ERK2 was rapid and weakly expressed in the presence of PMA alone and diminished with time. The lower panel shows that phosphorylation of ERK1/ERK2 was strongly expressed only in the presence of FN plus PMA after 5 minutes' treatment and was sustained up to 3 days, correlating with PPF. (B) Effect of signal inhibitors on phosphorylation of ERK1/ERK2. The inhibitors were added 1 hour prior to addition of PMA for 5 minutes. The upper panel shows that phosphorylation of ERK1/ERK2 was inhibited by PD, a MEK inhibitor (10 μM and 50 μM); GFX, a PKC inhibitor (5 μM and 25 μM); and SB, a p38 and JNK MAPK inhibitor (50 μM). No inhibition seen with SB (10 μM) and wortmannin (W), a PI3K inhibitor (100 nM and 500 nM). SFM indicates serum-free medium. The data are representative of 3 separate experiments.




Figure 4. Effect of signal inhibition on cell morphology. Cells were cultured in serum-free medium in the presence of FN. Cells were pretreated with inhibitors for 1 hour at 37°C; then PMA (10 ng/mL) was added and culture proceeded for 3 days. (A) Morphologic observation. Cells were visualized and measured by means of phase contrast microscopy at original magnification $\times 200$. Representative fields demonstrating the results of at least 10 separate experiments are shown. (B) Morphologic quantitation. Morphologic assay was carried out by means of a phase contrast microscope (see "Materials and methods"). The cells with PPF were defined as those bearing more than one cytoplasmic process that were at least twice the length of the cell body diameter. SFM indicates serum-free medium; PD, PD98059, an inhibitor of MEK MAPK (upstream of ERK); GFX, GF109203X, an inhibitor of PKC; SB, SB203580, an inhibitor of p38 and JNK; Wort, wortmannin, an inhibitor of PI3K. Graph depicts the means \pm SE from at least 10 experiments.

latter induced adhesion and PPF. Thus, while polyploidy or adhesion is essential for PPF, neither alone is sufficient to induce this morphologic change. Only FN/PMA costimulation induced a strong, rapid, and sustained phosphorylation of ERK1/ERK2 that lasted for at least 72 hours and correlated with full differentiation, including adhesion, spreading, size increase, polyploidization, and PPF. Since similar results were obtained with either serum/PMA or FN/PMA, the integrin ligand FN appears to be the component in serum responsible for the activation process leading to cell differentiation and PPF. Even though VN can also bind to $\alpha v\beta_3$, $\alpha v\beta_5$, and $\alpha IIb\beta_3$, which are also receptors for FN, it could not induce full differentiation of CHRF cells with PMA treatment; neither did CI bound to $\alpha IIb\beta_3$. The strong ERK1/ERK2 phosphorylation with FN/PMA was due to an amplification process resulting

from cross-talk between the integrin- and the PKC-generated signaling pathways.

Inhibitors of signaling pathways were used in order to clarify whether there was a causal relationship between ERK1/ERK2 activation and PPF. PD98059, an MEK inhibitor upstream of ERK1/ERK2, blocked the phosphorylation of ERK1/ERK2 as well as PPF, though polyploidy and adhesion were not affected. PPF therefore required not only adhesion to an FN matrix and polyploidy, but also sustained activation of ERK1/ERK2. A causal relationship was therefore demonstrated between ERK1/ERK2 activation and PPF.

The phenotypic differences between surface markers of differentiated and undifferentiated cells are related to the maturation process as reflected by the decrease of CD90 and CD33, early myeloid surface markers. The significant decrease of CD62P in differentiated cells may be due to its translocation to the PPF. CD62P is an α -granule protein in primary MKs and platelets that is expressed on the platelet surface following platelet activation. Its expression on the surface of CHRF cells is therefore not typical for a platelet-producing cell line.

Since adhesion and polyploidy are necessary, though not sufficient, for PPF, we investigated stimulation of MAPK pathways other than ERK1/ERK2. The JNK/SAPK pathway is usually activated in response to stress/apoptosis. In this study, phosphorylation of JNK1/SAPK, also induced by FN/PMA costimulation, appeared rapidly in concert with ERK1/ERK2 activation but disappeared after 24 hours, just when cells started to develop PPF. SB203580, an inhibitor of JNK1/SAPK, prevented JNK1/SAPK phosphorylation but did not affect differentiation features of CHRF cells or PPF, when used at a concentration of 10 μ M. Thus, though JNK1/SAPK activation correlates with CHRF differentiation, it is not involved in PPF. At a high concentration (50 μ M), SB203580 blocked PPF, probably via inhibition of ERK1/ERK2 (Figure 3B).

The p38 MAPK is activated when apoptosis, following differentiation, is triggered.⁴⁰ PI3K, on the other hand, is related to survival, growth, and differentiation.^{32,39} Since p38 MAPK and PI3K have been reported in some studies to be upstream of the pathway leading to ERK1/ERK2 activation,^{44,45} we investigated whether this was the case with CHRF cells. In this study, neither kinase was activated following treatment with the FN/PMA combination, and the inhibitors to the respective kinases did not affect cell differentiation or ERK1/ERK2 phosphorylation.




Figure 5. SAPK/JNK1 MAPK activation. Cells were cultured in FN/PMA for 3 days and analyzed by Western blot. (A) The upper panel shows that only phosphorylation of SAPK/JNK1 (46 kd) was expressed for up to 2 hours. (B) SB203580 (10 μ M and 50 μ M*), an inhibitor of SAPK/JNK added 1 hour prior to PMA treatment, blocked phosphorylation of SAPK/JNK1 (46 kd). SFM indicates serum-free medium. The data are representative of 3 separate experiments.

Recent reports have shown that TPO activated MK differentiation through the ERK MAPK pathway.⁴⁶ TPO was ineffective in promoting differentiation features in CHRF cells (data not shown), presumably owing to the lack of the c-Mpl receptor. Only stimulation with the nonphysiological agonist PMA in the presence of FN triggers differentiation.

The ultrastructure of PPF and released particles as well as the dysfunction of particles with platelet agonists demonstrates that the CHRF-288 cell line does not produce bona fide platelets. This transformed cell line, however, provides valuable information on the mechanism of MK differentiation, ploidy, and PPF and is useful

for a better understanding of molecular events associated with MK development and platelet production.

Acknowledgments

The authors are grateful to Drs Fern Tablin (University of California at Davis) and Michael A. Lieberman (University of Cincinnati, OH) for the CHRF-288 megakaryoblastic cell line; Mr Phil Lefebvre for helpful discussion; and Dr Mary Dunn for assistance.

References

- Vitrat N, Cohen-Solal K, Pique C, et al. Endomitosis of human megakaryocytes are due to abortive mitosis. *Blood*. 1998;91:3711-3723.
- Roy L, Coullin P, Vitrat N, et al. Asymmetrical segregation of chromosomes with a normal metaphase/anaphase checkpoint in polyploid megakaryocytes. *Blood*. 2001;97:2238-2247.
- Nagata Y, Muro Y, Todokoro K. Thrombopoietin-induced polyploidization of bone marrow megakaryocytes is due to a unique regulatory mechanism in late mitosis. *J Cell Biol*. 1997;139:449-457.
- Yamada E. The fine structure of the megakaryocyte in the mouse spleen. *Acta Anat (Basel)*. 1957;29:267-290.
- Zucker-Franklin D, Petrusson S. Thrombocytopoiesis-analysis by membrane tracer and freeze-fracture studies on fresh human and cultured mouse megakaryocytes. *J Cell Biol*. 1984;99:390-402.
- Tavassoli M. Megakaryocyte-platelet axis and the process of platelet formation and release. *Blood*. 1980;55:537-545.
- Behnke O. An electron microscope study of the rat megakaryocyte, II: some aspects of platelet release and microtubules. *J Ultrastruct Res*. 1969;26:111-129.
- Becker RP, DeBruyn PPH. The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation: a scanning electron microscopic investigation. *Am J Anat*. 1976;145:183-206.
- Radley JM, Scurfield G. The mechanism of platelet release. *Blood*. 1980;56:996-999.
- Leven RM. Megakaryocyte motility and platelet formation. *Scanning Microsc*. 1987;1:1701-1709.
- Italiano JE Jr, Lecine P, Shivasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. *J Cell Biol*. 1999;147:1299-1312.
- Ohno S, Akita Y, Hata A, et al. Structural and functional diversities of a family of signal transducing protein kinases, protein kinase C family; two distinct classes of PKC, conventional cPKC and novel nPKC. *Adv Enzyme Regul*. 1991;31:287-303.
- Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. *Science*. 1992;258:607-614.
- Long MW, Smolen JE, Szczepanski P, Boxer LA. Role of phorbol diesters in in vitro murine megakaryocyte colony formation. *J Clin Invest*. 1984;74:1686-1692.
- Long MW, Heffner CH, Williams JL, Peters C, Prochownik EV. Regulation of megakaryocyte phenotype in human erythroleukemia cells. *J Clin Invest*. 1990;85:1072-1084.
- Altalo R. Induced differentiation of K562 leukemia cells: a model for studies of gene expression in early megakaryoblasts. *Leuk Res*. 1990;14:501-514.
- Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. *Cell*. 1992;69:11-15.
- Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. *Annu Rev Cell Dev Biol*. 1995;11:549-599.
- Renshaw MW, Price LS, Schwartz MA. Focal adhesion kinase mediates the integrin signaling requirement for growth factor activation of MAP kinase. *J Cell Biol*. 1999;147:611-618.
- Aplin AE, Howe AK, Juliano RL. Cell adhesion molecules, signal transduction and cell growth. *Curr Opin Cell Biol*. 1999;11:737-744.
- Guadagno TM, Ohtsubo M, Roberts JM, Assoian RK. A link between cyclin A expression and adhesion-dependent cell cycle progression. *Science*. 1993;262:1572-1575.
- Juliano RL, Haskill S. Signal transduction from the extracellular matrix. *J Cell Biol*. 1993;120:577-585.
- Fornaro M, Zheng DQ, Languino LR. The novel structural motif Gln795-Gln802 in the integrin $\beta 1 C$ cytoplasmic domain regulates cell proliferation. *J Biol Chem*. 1995;270:24666-24669.
- Boudreau N, Sympton CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. *Science*. 1995;267:891-893.
- Chen Q, Kinch MS, Lin TH, Burridge K, Juliano RL. Integrin-mediated cell adhesion activates mitogen-activated protein kinases. *J Biol Chem*. 1994;269:26602-26605.
- Schlaepfer DD, Hanks SK, Hunter T, van der Geer P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. *Nature*. 1994;372:786-791.
- Lin TH, Chen Q, Howe A, Juliano RL. Cell anchorage permits efficient signal transduction between Ras and its downstream kinases. *J Biol Chem*. 1997;272:8849-8852.
- Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. *Science*. 1995;270:1326-1331.
- Beyaert R, Cuenda A, Berghe WV, et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor. *EMBO J*. 1996;15:1914-1923.
- Takenaka K, Moriguchi T, Nishida E. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. *Science*. 1998;280:599-602.
- Wang Y, Huang S, Sah VP, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38/mitogen-activated protein kinase family. *J Biol Chem*. 1998;273:2161-2168.
- Duronio V, Scheid MP, Ettinger S. Downstream signaling events regulated by phosphatidylinositol 3-kinase activity. *Cell Signal*. 1998;10:233-239.
- Terstappen LW, Safford M, Loken MR. Flow cytometric analysis of human bone marrow, III: neutrophil maturation. *Leukemia*. 1990;4:657-663.
- Lefebvre P, Winter JN, Rademaker AW, Goolsby C, Cohen I. In vitro production of megakaryocytes from PIXY321 versus GM-CSF-mobilized peripheral blood progenitor cells. *Stem Cells*. 1997;15:112-118.
- Levine RF, Fedorko ME. Isolation of intact megakaryocytes from guinea pig femoral marrow: successful harvest made possible with inhibitors of platelet aggregation; enrichment achieved with a two-step separation technique. *J Cell Biol*. 1976;69:159-172.
- Leven RM, Rodriguez A. Immunomagnetic bead isolation of megakaryocytes from guinea-pig bone marrow: effect of recombinant interleukin-6 on size, ploidy and cytoplasmic fragmentation. *Br J Haematol*. 1991;77:267-273.
- Fugman DA, Witte DP, Jones CLA, Aronow BJ, Lieberman MA. In vitro establishment and characterization of a human megakaryoblastic cell line. *Blood*. 1990;75:1252-1261.
- Williams SF, Lee WJ, Bender JG, et al. Selection and expansion of peripheral blood CD34⁺ cells in autologous stem cell transplantation for breast cancer. *Blood*. 1996;87:1687-1691.
- Wang JF, Park IW, Groopman JE. Stromal cell-derived factor-1 α stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. *Blood*. 2000;95:2505-2513.
- Kanasaki H, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells. *Biol Reprod*. 2000;62:1468-1494.
- Yue TL, Wang CL, Gu JL, et al. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. *Circ Res*. 2000;86:692-699.
- Borner C, Eppenberger U, Wyss R, Fabbro D. Continuous synthesis of two protein kinase C-related proteins after down-regulation by phorbol esters. *Proc Natl Acad Sci U S A*. 1988;85:2110-2114.
- Hu X, Moscinski LC, Valkov NI, et al. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. *Cell Growth Differ*. 2000;11:191-200.
- Jiang K, Zhong B, Gilvary DL, et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. *Nat Immunol*. 2000;1:419-425.
- Ludwig S, Hoffmeyer A, Goebeler M, et al. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. *J Biol Chem*. 1998;273:1917-1922.
- Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. *Blood*. 1999;94:1273-1282.

Appendix V

Isaac Cohen - DAMD-98-1-8327

METHODS IN MOLECULAR BIOLOGY™

Cytokines and Colony Stimulating Factors

Methods and Protocols

Edited by

Dieter Körholz

and

Wieland Kiess

*Department of Pediatrics, University of Leipzig,
Leipzig, Germany*

Humana Press  **Totowa, New Jersey**

2003

Large-Scale Ex Vivo Expansion of Human Megakaryocytes for Clinical Use

Phil Lefebvre and Isaac Cohen

1. Introduction

This chapter will describe a method used to produce human megakaryocytes *in vitro* (see Fig. 1), in high yield, for a clinical product to supplement progenitor cell transplants. Producing significant numbers of megakaryocytes from human progenitor cells requires specific combinations of cytokines to promote their proliferation and maturation *in vitro*. Thrombopoietin (TPO) is the primary regulator of megakaryocytopoiesis (1-6). Other cytokines, including interleukin-3 (IL-3), IL-6, IL-11, stem cell factor (SCF; also known as *kit*-ligand), and granulocyte-macrophage colony stimulating factor (GM-CSF) are also capable of promoting megakaryocytopoiesis and will synergize with TPO to increase megakaryocyte proliferation (reviewed in ref. 7).

Properly maintained (e.g., refed and split at regular intervals), static *in vitro* liquid cultures of purified human bone marrow CD34+ cells can take approx 2 wk for the progenitor cells to terminally differentiate and undergo apoptosis (8). In the presence of TPO alone, these cultures can reach 90+% CD41+ (the primary surface marker for megakaryocytes), but the range of megakaryocyte production and maturation is highly variable and is dependent on culture conditions and the quality of starting material. Human umbilical cord blood CD34+ cells are capable of greater proliferation, but less capable of producing high-ploidy megakaryocytes. Human peripheral blood CD34+ cells perform similarly to bone marrow cells, although the quality of the patient's progenitor cells will ultimately determine productivity (9). Adding other mitogenic cytokines, such as IL-3, will significantly decrease the frequency of CD41+




Fig. 1. Phase-contrast image of an 85% pure, 12-d human megakaryocyte culture. The white arrow points to a megakaryocyte that is beginning to form proplatelet extensions. The black arrow points to a megakaryocyte that has completed this process and shed platelets. Magnification = 400 \times .

cells, but will even more significantly increase the rate of cell expansion, resulting in a net increase in total megakaryocytes produced (10). Although numerous cytokines can be combined to promote *ex vivo* expansion of megakaryocytes (11), a significant expansion of megakaryocytes can be achieved with as little as two or three cytokines (10,12-14), which may prove more practical in a clinical setting.

Unlike murine megakaryocytes, no culture condition has yet been shown to promote normal polyploid nuclear maturation of human megakaryocytes *in vitro*, defined as a modal ploidy of 16 *N* or 8 pairs of chromosome sets. Also, there is an inverse relationship between proliferation and maturation of cultured human megakaryocytes (12-15). Culturing with TPO alone, which is not a great promoter of cell proliferation, will generate a higher level of megakaryocyte maturation than when combined with more mitogenic cytokines, though a recent article has shown that stromal-cell-derived factor 1 can increase the number and ploidy of megakaryocytes derived *in vitro* from human CD34+ cells cultured in the presence of TPO at low cell concentrations under low oxygen tension (16), although a normal 16*N* modal ploidy was still not achieved.

We and others (10,11) have found that serum-free medium can be more productive for *ex vivo* expansion than medium containing plasma. Serum-free

medium would also be preferable for ex vivo expansion of cells for transplant, because of the risks associated with allogeneic blood transfusions, and because it is a more consistent and well-defined product. Serum derived from clotted blood is not appropriate for promoting megakaryocyte expansion, as it contains platelet-derived factors inhibitory to megakaryocyte growth, such as transforming growth factor β , β -thromboglobulin, and platelet factor 4, all released from activated platelets (17-19). If cost is a factor, autologous, heparinized platelet-free plasma or autologous serum derived from calcium-clotted platelet-free plasma could also be suitable for culturing megakaryocytes, as it eliminates the risk associated with allogeneic blood transfusion.

2. Materials

2.1. Media, Buffers, and Cytokines

1. Culture medium: X-vivo 20 serum-free medium (BioWhittaker, Walkersville, MD) (*see Note 1*).
2. Thawing medium: X-vivo 20, containing 10 IU preservative-free heparin and 10 μ g/mL of DNase.
3. Growth factors used (final concentration): TPO (100 ng/mL), IL-3 (10 ng/mL), Flt-3 ligand, (Flt-3L, 100 ng/mL). Aliquots of each reconstituted cytokine are stored at -70°C until needed. Thawed aliquots can be kept at 4°C for up to 2 wk.
4. Phosphate-buffered saline (PBS), without calcium or magnesium.
5. Hypotonic citrate; 1 mg/mL of sodium citrate in deionized water.
6. DNA dye; propidium iodide or 7-aminoactinomycin D (7-AAD).

2.2. CD34+ Cell Selection

Miltenyi MACS CD34+ selection system appropriate for the quantity of cells used.

2.3. Colony Assays

Needed if the primitive progenitor population is of interest. We have tested several different clonogenic assay protocols and have found the kits from Stem Cell Technologies (Vancouver, BC, Canada) for CFU-MK (MegaCult C) and CFU-GM (MethoCult) to be the most efficient.

2.4. Quantitative Cell Analysis

1. 1% Trypan blue (Sigma) in saline, for cell enumeration and determination of viability.
2. Anti-human CD34 and CD41 antibodies, coupled to different fluorochromes, for flow-cytometric analysis. A comparable isotypic antibody, labeled with the same fluorochrome, is used as a negative control.

2.5. Instrumentation

1. 37°C Water bath.
2. Class B sterile tissue culture hood.
3. Clinical bench centrifuge.
4. 37°C tissue culture incubator at 5% CO₂.
5. Variable adjustable electronic pipettor, EDP, Rainin.
6. Vacuum-driven automatic pipet device.

2.6. Supplies

1. Sterile pipet tips with aerosol barrier.
2. Sterile individually wrapped polypropylene transfer pipets.
3. 2-mL, 5-mL, 10-mL, 25-mL Sterile individually wrapped polystyrene pipets with an aerosol barrier.
4. Sterile centrifuge tubes.
5. 1-cm³, 3-cm³, 10-cm³, 20-cm³, 30-cm³, 60-cm³ sterile Luer-Lok™ syringes.
6. VueLife Teflon tissue culture bags, 1 L (270-mL nominal capacity) and 7-mL capacity, American Fluoroseal Corporation. Other sizes are also available, including custom sizes.
7. Luer-Lok connector tubing, available from American Fluoroseal Corp.
8. Sterile threaded Luer-Lok cannulas (BD Interlink System; Becton Dickinson product no. 303369).
9. Interlink Luer-Lok injection site (Baxter Healthcare product no. 2N3379).

3. Method

3.1. CD34 Cell Selection

For large-scale clinical use, the CliniMACS clinical-grade system is preferred. It is approved for clinical use in the European Community, but is presently under evaluation for clinical use in the United States. Smaller-scale systems are available for preclinical or basic research use. The manufacturer-supplied laboratory protocol is straightforward and easy to follow and should be followed closely to ensure successful CD34 cell purification. Purity of over 90% with high yield (70+%) is common with all MACS systems, when used before the expiration date.

3.2. Sample Thawing

If cells were frozen after purification for storage and use at a later date, then they will need to be carefully thawed, as freezing and thawing can damage cells.

1. Each frozen CD34+ cell unit is placed into a resealable plastic bag and the bag closed, to prevent any contaminating water seepage into the tube.

2. The sealed bag with the tube is then placed in a 37°C water bath and gently agitated until the cell suspension has thawed 90%, to a small ball of ice (approx 3–4 min for a 5-mL tube).
3. The bag is wiped dry and transferred to a Class B sterile tissue culture hood, where the tube is removed from the bag aseptically. (See Notes 2–4.)

3.3. Sample Washing

1. In the sterile tissue culture hood, the contents of a 5-mL tube of thawed cells is transferred by gentle addition into a sterile 50-mL centrifuge tube using a sterile polypropylene transfer pipet.
2. The cells are diluted 1:10 with 45 mL of cold thawing medium.
3. The tube is sealed and the cells gently mixed.
4. The suspension is centrifuged at 260g for 10 min at 4°C.
5. The cell pellet is resuspended in 3 mL of X-vivo 20 using a sterile polypropylene transfer pipet.
6. Dilute the cell suspension to 50 mL with X-vivo 20 (not thawing medium) by decanting fresh medium.
7. The cell suspension is centrifuged again at 260g for 10 min at 4°C.
8. The cell pellet is resuspended in 3 mL of X-vivo 20 using a sterile polypropylene transfer pipet.

3.4. Nucleated Cell Count

1. A 50-μL sample for cell concentration analysis is taken using a sterile pipet tip with an aerosol barrier.
2. The sample is diluted with trypan blue so that the cell concentration in the trypan blue is not more than 10^6 cells/mL.
3. Apply 10–12 μL of trypan blue cell suspension to a hemacytometer.
4. Determine the cell concentration and viability (cells that appear blue are not viable) using a phase-contrast microscope.
5. The final volume required to achieve a cell concentration of 400,000 cells/mL is calculated, based on the cell count.

3.5. Culture Preparation

1. The cells are injected using a syringe connected to a Luer-Lok cannula, through the Interlink injection port, into a Teflon bag of appropriate size (see Fig. 2).
2. The bag's nominal volume is adjusted with bag clip barriers so as to contain a volume sufficient to suspend the cells at 400,000 cells/mL at an average fluid height of 1 cm.
3. X-vivo 20 and sufficient cytokines to achieve a final concentration of 100 ng/mL Flt-3L, 100 ng/mL TPO, and 10 ng/mL IL-3 is then added using a 60-cm³ syringe attached via Luer-Lok connections to the bag to reach the final volume. (See Note 5.)




Fig. 2. Syringe-bag connection system. Inset: exploded view showing (from left to right) Luer-Lok 60-cm³ syringe, Interlink threaded lock cannula, Interlink injection site, and Luer-Lok opening of Teflon bag.

3.6. Culture Maintenance

Cells should be assayed at least every other day to ensure that they have not proliferated beyond the capacity of the culture medium. In our experience, X-vivo 20 has a maximum cell capacity of up to 2×10^6 cells/mL, depending on the quality of the cells used.

1. After gently agitating the bag to resuspend the cells, a 5-mL aliquot is removed using a syringe and injected into a 7-mL Teflon bag for use as a test sample.
2. Both bags are stored in a 37°C tissue culture incubator at 5% CO₂ used solely for the purpose of clinical patient sample preparation. (See Notes 6–8.)

3.7. Refeeding the Culture

When cells have proliferated beyond the culture medium's limit, they will need to be split and refed.

1. Count the cells as in Subheading 3.4.
2. Calculate the amount of medium and cytokines required to readjust the cell concentration to 400,000 cells/mL.
3. Calculate the area required to maintain a 1-cm culture height and readjust the bag clips to that position.
4. Add that amount to the culture bag using the Luer-Lok syringes and cannula connectors.
5. If the culture medium required exceeds the capacity of the bag, additional bags are then attached to the culture bag using the Luer-Lok connection tubing, and an appropriate fraction of cell suspension is transferred to the new bag (see Fig. 3). (See Note 9.)




Fig. 3. Bag-bag connection system. Inset: Exploded view. A flexible tube with Luer-Lok connectors on each end is substituted for the syringe in Fig. 2.

3.8. Cell Harvest

When the designated culture period has passed, the sample is transferred to an appropriate vessel and gently washed, PBS with 1% albumin, or other clinically approved procedure. Cells can be washed in an automated cell washer or centrifuged using centrifuge tubes or bottles of sufficient capacity to contain the culture. The appropriate procedure needs to be determined empirically, based on culture size, equipment available, and whether a closed system is required for clinical use. Three wash steps should be used ensure that no residual cytokine remains in any product designated for transplant. (See Note 10.)

3.9. Cell Analysis

Flow cytometry is the most efficient way of measuring phenotype expression of cells in a liquid culture. Megakaryocytes can be difficult to assay, however, because of their fragility and great variation in size. Cells that may have been exposed to platelets (e.g., peripheral blood cells, umbilical cord cells, or cells in platelet-producing megakaryocyte cultures) should be incubated in EDTA-containing buffer to disassociate any adherent platelets (20). Then, standard flow-cytometric techniques can be used to assay megakaryocyte proliferation. (See Note 11.)

1. Place cell medium containing 100,000 cells into a 12 × 75-mm test tube, appropriate for use on a flow cytometer.
2. Add 2 mM EDTA and incubate for at least 15 min at room temperature. Longer incubations may be necessary if platelet contamination is high.
3. Fill the tube with PBS and centrifuge at 260g for 5 min at 4°C.

4. Remove all supernatant and add the recommended amount of fluorochrome-labeled antibody. Vortex gently.
5. Incubate for 15 min at 4°C in the dark.
6. Fill the tube with PBS and centrifuge at 260g for 5 min at 4°C.
7. Remove supernatant, resuspend the cells in 0.5–1 mL of PBS and assay by flow cytometry immediately.
8. If megakaryocyte ploidy measurement is desired, substitute 1 mL of hypotonic citrate buffer for the PBS. Add 1 µg/mL of propidium iodide or 7-AAD. Incubate an additional 30 min at room temperature before assaying.

4. Notes

1. We have tested numerous serum-free media and have found X-vivo 20 to be the most conducive to megakaryocyte proliferation. However, technology can continue to evolve, so it would be expected that improved media should become available in the future. Further testing would be warranted to find the medium optimal for each protocol.
2. It is our experience that mononuclear cells are more fragile during freezing and thawing than selected CD34 cells. In either case, DNase is recommended for the thawing medium to remove DNA released from lysed cells. However, work within the recommended levels, as too much DNase can be harmful to cells.
3. We and others (21) have found the Miltenyi CD34+ MACS selection systems to be the most efficient. The systems available range from a total cell capacity of 10^5 – 10^{11} cells. We have used several different Miltenyi systems, all with excellent results.
4. The Fluoroseal Teflon bags are impermeable to liquid, but permeable to gas. This allows adequate gas exchange while all ports remain fully sealed, so that vapor cannot escape the bag. What this means is that liquid medium loss is not a problem, so it is not necessary to keep water in the incubator for humidity, reducing contamination risk.
5. For a 1-L Teflon bag, only 270 mL is used so that the culture medium height remains at approx 1 cm, which has been determined to be optimal for culture performance. Lower heights reduce cell productivity, whereas higher media heights waste reagent. The use of bag clips allows for volumes less than 270 mL to be used in the 1-L bags, and then removed as the culture expands and is refed. American Fluoroseal supplies appropriate clips, but any plastic clip that would not damage the plastic bags would work.
6. It has been our experience that ex vivo cultured cells derived from oncology patients will often show a dramatic drop in viable cell numbers in the first few days of a culture. This phenomenon is true whether the cells were unselected mononuclear cells or selected CD34 cells and it is highly variable.
7. The use of a smaller, 7-mL bag is to be able to monitor culture progress without needing to access the main culture, reducing the risk of contamination. In our experience, the phenotypic development of the cells in either bag is identical.

8. We have found that megakaryocyte proliferation is enhanced with an initial seeding density of 400,000 CD34 cells/mL, compared to lower seeding densities. The culture conditions described have a total cell capacity in the range of up to 2×10^6 cells/mL (fivefold expansion) before having a significant negative impact on cell proliferation and viability. However, cell concentration may need to be readjusted after only a twofold to threefold expansion of viable cells to minimize any negative effects of large numbers of nonviable cells. This is most often in cases of less healthy or damaged cell samples that rapidly degenerate into nonviable states.
9. The easiest way to transfer expanded cells from one bag to another is by attaching the two bags together with a Luer-Lok connector tube and suspending the full bag so that medium runs down into the empty bag. When the cell culture appears to be equally distributed in each bag, they should be weighed and equilibrated by weight. This avoids excessive opening and taping of the bags, reducing contamination risk.
10. Once mature megakaryocytes are generated, care should be taken in handling the culture, as large high-ploidy megakaryocytes are fragile. Avoid extremes of handling and vortexing, if preservation of the larger, more mature megakaryocytes is important.
11. Although there are many procedures for fixing and permeabilizing megakaryocytes, the method using hypotonic citrate is the easiest and best preserves the large ploidy megakaryocytes, because of significantly less manipulation.

References

1. Bartley, T. D., Bogenberger, J., Hunt, P., Li, Y. S., Lu, H. S., Martin, F., et al. (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. *Cell* 77(7), 1117-1124.
2. de Sauvage, F. J., Hass, P. E., Spencer, S. D., Malloy, B. E., Gurney, A. L., Spencer, S. A., et al. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. *Nature* 369(6481), 533-538.
3. Kaushansky, K., Lok, S., Holly, R. D., Broudy, V. C., Lin, N., Bailey, M. C., et al. (1994) Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. *Nature* 369(6481), 568-571.
4. Kuter, D. J., Beeler, D. L., and Rosenberg, R. D. (1994) The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. *Proc. Natl. Acad. Sci. USA* 91(23), 11,104-11,108.
5. Lok, S. and Foster, D. C. (1994) The structure, biology and potential therapeutic applications of recombinant thrombopoietin. *Stem Cells* 12(6), 586-598.
6. Wendling, F., Maraskovsky, E., Debili, N., Florindo, C., Teepe, M., Titeux, M., et al. (1994) cMpl ligand is a humoral regulator of megakaryocytopoiesis. *Nature* 369(6481), 571-574.
7. Hoffman, R. (1997) The role of other hemopoietic growth factors and the marrow microenvironment in megakaryocytopoiesis, in *Thrombopoiesis and Thrombopoi-*

- etins: Molecular, Cellular, Preclinical, and Clinical Biology* (Kuter, D. J., Hunt, P., Sheridan, W., and Zucker-Franklin, D., eds.), Humana, Totowa, NJ, pp. 165–178.
8. Zauli, G., Vitale, M., Falcieri, E., Gibellini, D., Bassini, A., Celeghini, C., et al. (1997) In vitro senescence and apoptotic cell death of human megakaryocytes. *Blood* 90(6), 2234–2243.
 9. Lefebvre, P., Winter, J. N., Rademaker, A. W., Goolsby, C., and Cohen, I. (1997) In vitro production of megakaryocytes from PIXY321 versus GM-CSF-mobilized peripheral blood progenitor cells. *Stem Cells* 15(2), 112–118.
 10. Lefebvre, P., Winter, J. N., Kahn, L. E., Giri, J. G., and Cohen, I. (1999) Megakaryocyte ex vivo expansion potential of three hematopoietic sources in serum and serum-free medium. *J. Hematother.* 8(2), 199–208.
 11. Bertolini, F., Battaglia, M., Pedrazzoli, P., Da Prada, G. A., Lanza, A., Soligo, D., et al. (1997) Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. *Blood* 89(8), 2679–2688.
 12. Schattner, M., Lefebvre, P., Mingoelli, S. S., Goolsby, C. L., Rademaker, A., White, J. G., et al. (1996) Thrombopoietin-stimulated ex vivo expansion of human bone marrow megakaryocytes. *Stem Cells* 14(2), 207–214.
 13. van den Oudenrijn, S., de Haas, M., Calafat, J., van der Schoot, C. E., and von dem Borne, A. E. G. K. (1999) A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for 14. transfusion purposes. *Br. J. Haematol.* 106(2), 553–563.
 14. Lefebvre, P., Winter, J. N., Meng, Y. R., and Cohen, I. (2000) Ex vivo expansion of early and late megakaryocyte progenitors. *J. Hematother. Stem Cell Res.* 9(6), 913–921.
 15. Levin, J., Levin, F. C., Penington, D. G., and Metcalf, D. (1981) Measurement of ploidy distribution in megakaryocyte colonies obtained from culture: with studies of the effects of thrombocytopenia. *Blood* 57(2), 287–297.
 16. Guerriero, R., Mattia, G., Testa, U., Chelucci, C., Macioce, G., Casella, I., et al. (2001) Stromal cell-derived factor 1alpha increases polyploidization of megakaryocytes generated by human hematopoietic progenitor cells. *Blood* 97(9), 2587–2595.
 17. Mitjavila, M. T., Vinci, G., Villeval, J. L., Kieffer, N., Henri, A., Testa, U., et al. (1988) Human platelet alpha granules contain a nonspecific inhibitor of megakaryocyte colony formation: its relationship to type beta transforming growth factor (TGF-beta). *J. Cell. Physiol.* 134(1), 93–100.
 18. Gewirtz, A. M., Calabretta, B., Rucinski, B., Niewiarowski, S., and Xu, W. Y. (1989) Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide. *J. Clin. Invest.* 83(5), 1477–1486.
 19. Abgrall, J. F., Han, Z. C., Sensebe, L., Le Gall, G., Guern, G., Renard, I., et al. (1991) Inhibitory effect of highly purified human platelet beta-thromboglobulin on in vitro human megakaryocyte colony formation. *Exp. Hematol.* 19(3), 202–205.

20. Dercksen, M. W., Weimar, I. S., Richel, D. J., Breton-Gorius, J., Vainchenker, W., Slaper-Cortenbach, C. M., et al. (1995) The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets. *Blood* 86(10), 3771-3782.
21. de Wynter, E. A., Coutinho, L. H., Pei, X., Marsh, J. C., Hows, J., Luft, T., et al. (1995) Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems. *Stem Cells* 13(5), 524-532.